research and reports in medicinal chemistry

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals

Medicinal chemistry articles from across Nature Portfolio

Medicinal chemistry deals with the design, optimization and development of chemical compounds for use as drugs. It is inherently a multidisciplinary topic — beginning with the synthesis of potential drugs followed by studies investigating their interactions with biological targets to understand the medicinal effects of the drug, its metabolism and side-effects.

Related Subjects

• Chemical libraries
• Cheminformatics
• Computational chemistry
• Drug delivery
• Drug discovery and development
• Lead optimization
• Pharmacology
• Structure-based drug design
• Target identification
• Target validation

Latest Research and Reviews

Divergent access to 5,6,7-perifused cycles

The lack of efficient and diverse synthesis strategy has hindered the study of perifused cycles. Here, the authors report a metal-catalyzed cascade electrocyclization to access 5,6,7-perifused cycles, and demonstrated the versatility of this protocol in the late-stage modification of pharmaceuticals.

• Jingpeng Han
• Yongjian Yang
• Baosheng Li

Structural basis of lipid-droplet localization of 17-beta-hydroxysteroid dehydrogenase 13

Hydroxysteroid 17-beta-dehydrogenase 13 (HSD17B13) is a hepatic lipid droplet-associated enzyme that is upregulated in patients with non-alcoholic fatty liver disease. Here, the authors report crystal structures of HSD17B13 and its complexes with two series of inhibitors.

• Shenping Liu
• Ruth F. Sommese
• Michelle F. Clasquin

Using macromolecular electron densities to improve the enrichment of active compounds in virtual screening

Virtual screening methods for drug discovery typically rely on static structures and lack efficient incorporation of dynamic information exhibited in experimental electron densities. Here, the authors develop an approach utilizing multi-resolution experimental electron density maps to screen docking poses, with the effectiveness demonstrated in both the improvement of active compound enriching exhibited in the test using DUD-E data set and the identification of four inhibitors of Covid-19 3CLpro with IC50 of up to 1.9 μM.

The amide derivative of anticopalic acid induces non-apoptotic cell death in triple-negative breast cancer cells by inhibiting FAK activation

• Pornsuda Chawengrum
• Natthaorn Luepongpatthana
• Somsak Ruchirawat

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation

Lenalidomide is effective for treating several hematological cancers but has teratogenic effect on the fetus. Here, the authors identify modifications that make lenalidomide more selective and effective when used as a stand-alone molecular glue or integrated in PROTACs.

• Satoshi Yamanaka
• Hirotake Furihata
• Tatsuya Sawasaki

Ni 2+ and Cu 2+ complexes of N-(2,6-dichlorophenyl)-N-mesityl formamidine dithiocarbamate structural and functional properties as CYP3A4 potential substrates

• Segun D. Oladipo
• Sizwe J. Zamisa
• Monsurat M. Lawal

News and Comment

Is classifying ssc-ild drugs as either immunosuppressive or anti-fibrotic misleading.

• Kristofer Andréasson
• Viggo Hamberg
• Gunilla Westergren-Thorsson

Anticancer platinum-based photo-oxidants in a new light

Pharmacologically inactive prodrugs that can be activated by near-infrared light are attractive candidates for clinical applications. Now, platinum-based photo-oxidants have been shown to eradicate tumours in mice with a new mode of action.

• Gloria Vigueras
• Gilles Gasser

A miniaturized toolkit for medicinal chemists

The most popular reactions used by medicinal chemists are often incompatible with nanoscale ultrahigh-throughput experimentation (ultraHTE). Now, a set of ultraHTE-amenable reaction conditions is reported for four of the most important transformations in drug discovery, and their generality and scalability tested on a range of complex natural products and drug candidates.

Isolable iminium salts enable access to elusive piperidines

Cyclic iminium salts are used as versatile intermediates in the synthesis of diverse N -(hetero)aryl piperidines. This method facilitates the C2 and/or C3 functionalization of the piperidine backbone with motifs relevant to medicinal chemistry, enabling the exploration of previously inaccessible chemical space for the discovery of medicines.

Sorry, this item is not (bio)available

By breaking a clinical candidate into its substructures, fragments with poor bioavailability profiles can be identified, removed and replaced in a compound before entering the laboratory.

• Stephanie Greed

Simplifying the synthesis of aryl C -glycosides

A modular and general method to make unprotected aryl C -glycosides with high stereoselectivity from simple starting materials has been developed based on photoredox, Ni-catalysed cross-coupling. Key to success is the use of an allyl glycosyl sulfone in combination with tolyl sulfinate as the synthetic equivalent of a glycosyl anion.

Quick links

• Explore articles by subject
• Guide to authors
• Editorial policies

Maintenance work is planned for Thursday 31st August 2023 from 11:00 to 12:00 (BST).

During this time the performance of our website may be affected - searches may run slowly and some pages may be temporarily unavailable. If this happens, please try refreshing your web browser or try waiting two to three minutes before trying again. We apologise for any inconvenience caused and thank you for your patience.

RSC Medicinal Chemistry  

About RSC Medicinal Chemistry

Research and review articles in medicinal chemistry and related drug discovery science. Editor-in-chief: Mike Waring Impact Factor: 4.1 Time to first decision (peer reviewed only): 40 days

Find an article

Find issues by year (2020 - present), related journals.

• MedChemComm (2010-2019)

Journal information

• About this Journal
• People and Contacts
• Editorial Board
• Subscription Information
• Follow   |    |  

Advertisements

Journals, books & databases

• Our journals

RSC Medicinal Chemistry

The journal for research and review articles in medicinal chemistry and related drug discovery science

You can find details about how to access information remotely in this step-by-step guide . The guide will also help if for any reason you have difficulty accessing the content you want.

What would you like to know about this journal?

RSC Medicinal Chemistry  is a Transformative Journal and Plan S compliant

Impact factor: 4.1*

Time to first decision (all decisions): 14.0 days**

Time to first decision (peer reviewed only): 40.0 days***

Editor-in-Chief: Mike Waring

CiteScore: 7.5****

Open access publishing options available

Read this journal

Submit an article

Sign up for regular email alerts

View all journal metrics

Publish open access

Meet the team

Journal scope.

RSC Medicinal Chemistry  publishes significant research in medicinal chemistry and related drug discovery science.

Research articles published in  RSC Medicinal Chemistry  must show a breakthrough or significant advance on previously published work, or bring new thinking or results that will have a strong impact in their field.

Examples of areas within the journal's scope are:

• Design, synthesis and biological evaluation of novel chemical entities or biotherapeutic modalities. To be suitable for publication these must exhibit significant potential as new pharmacological agents, tools, probes or potential drugs.
• Modifications of known chemical entities or biotherapeutic modalities that result in a significantly greater understanding of their structure-activity relationships, an improvement of their properties or provide other information of significant value, for example, the identification of a new target or mode of action for a known agent. Routine modifications with minimal or no improvement are not suitable for  RSC Medicinal Chemistry .
• Novel methodologies and technologies in the broader chemical and biological sciences (for example, enabling synthetic chemistry, chemical biology, -omics sciences, nanoscience) with application to drug discovery, target identification or elucidation of the mechanism of action. Biological studies should present sufficient innovation with respect to the chemistry.
• Computational studies are welcome where they significantly advance medicinal chemistry knowledge. Studies that use established computational methods should include an original prediction and be accompanied by new experimental data which validates the prediction made. Studies that report novel computational methodology must demonstrate its use in medicinal chemistry through comparison with experimental data. Computational research that does not clearly relate the results obtained to experimental data or that has no demonstrated utility (or where the utility is unlikely to advance the field significantly) is not suitable for RSC Medicinal Chemistry. Docking studies presented without experimental data are not suitable for publication in the journal.
• Studies that examine the effect of the molecular structure of a compound on pharmacokinetic behaviour and pharmacodynamics.
• Studies that present new insights into drug design based on analysis of existing experimental datasets or new theoretical approaches if supported by experimental evidence.
• Studies presenting new drug delivery systems with novel chemical agents are welcomed, in particular those that involve chemical modification of the delivery system of conjugation with novel delivery vectors. Those that focus solely on formulations of known drugs are not suitable for publication in RSC Medicinal Chemistry.

Note that studies where new or existing compounds are tested as pharmacological agents will only be considered if they are carried out in the presence of clear positive and negative controls. Studies of this type should include a clearly defined and hypothesis-driven compound design rationale. Potential antimicrobial agents should be tested for cytotoxicity and activity against non-related pathogens.

To help editors and referees assess the significance of each submitted manuscript we ask all authors on submission to provide a brief statement of significance. This should contain one sentence to summarise the most important finding(s) in the manuscript and a second sentence to say why this is a significant advance in the field. This significance statement should focus specifically on the importance of the piece of research being submitted, rather than the importance of the field.

RSC Medicinal Chemistry Lectureship award

This Lectureship celebrates outstanding early career researchers who have made significant contributions in the fields of medicinal chemistry and drug discovery. The RSC Medicinal Chemistry Lectureship is awarded annually through a process whereby nominations of candidates are invited from our community.

You can read about eligibility, how to nominate, deadlines for nominations and see all of our lectureship winners.

Find out who is on the editorial and advisory boards for the  RSC Medicinal Chemistry  journal.

Editor-in-chief

Mike Waring , Newcastle University, UK

Associate editors

Cynthia Dowd , George Washington University, USA

Maria Duca , Université Côte d’Azur - CNRS, France

Sally-Ann Poulsen , Griffith University, Queensland, Australia

Jian Zhang , Shanghai Jiao Tong University School of Medicine, China

Editorial board members

Hayley Binch , Hoffman-La Roche, Switzerland

Paola Castaldi , LifeMine Therapeutics, USA

Matthew Fuchter , Imperial College London, UK

Lyn Jones , Dana-Farber Cancer Institute, USA

Jean-Louis Reymond , University of Bern, Switzerland

Timor Baasov , Israel Institute of Technology, Israel

Andreas Bender , University of Cambridge, UK

Julian Blagg , Institute of Cancer Research, UK

Margaret Brimble , University of Auckland, New Zealand

Mark Bunnage , Vertex, USA

Christopher Burns , Certa Therapeutics, Australia

Andrea Cavalli , University of Bologna, Italy

Young-Tae Chang , POSTECH, South Korea

James Crawford , Genentech Inc, USA  

Matthew Duncton , Rigel Pharmaceuticals Inc

Stephen Frye , University of North Carolina at Chapel Hill, USA

Sylvie Garneau-Tsodikova , University of Kentucky, USA

Barry Gold , University of Pittsburgh, USA

Jayanta Haldar , Jawaharlal Nehru Centre for Advanced Scientific Research, India

Gyoonhee Han , Yonsei University, Korea

Mike Hann , GSK Medicines Research Centre, Stevenage, UK

Christian Heinis , EPFL, Switzerland

Laura H. Heitman , Leiden University, Netherlands

Yoshinori Ikeura , Axcelead Drug Discovery Partners, Japan

Ahmed Kamal , NIPER, Hyderabad, India

Robert Langer , MIT, USA

Steven V Ley , University of Cambridge, UK

María Luz López Rodríguez , Complutense University of Madrid, Spain

Christa Muller , University of Bonn, Germany

Roberto Pellicciari , University of Perugia, Italy

David Rees , Astex Therapeutics, Cambridge, UK

Motonari Uesugi , Kyoto University, Japan

John C Vederas , University of Alberta, Canada

Paul Wender , Stanford University, USA

Zhen Yang , Peking University, China

Ming-Qiang Zhang , Amgen, Shanghai, China

Rebecca Garton , Executive Editor

Jack Washington , Deputy Editor

Emily Cuffin-Munday , Development Editor

Sarah Whitehouse , Editorial Production Manager

Nicola Burton , Publishing Editor

Tom Cozens , Publishing Editor

Katie Fernandez , Publishing Editor

Ryan Kean , Publishing Editor

Roxane Owen , Publishing Editor, ORCID 0000-0002-4553-233X

Alex Rowles , Publishing Editor

Andrea Whiteside , Publishing Assistant

Sam Keltie, Publisher

Article types

RSC Medicinal Chemistry  publishes:

• Research articles
• Review articles

Research article

All new research in  RSC Medicinal Chemistry  is published in the Research article format. Research articles have no page limits, although most articles fall between 4 and 10 journal pages (approximately 10–25 pages of double-spaced text). Research Articles encompass both full paper and communication styles. Where a communication style article is submitted the work should be of enough importance to merit urgent publication before the full study is complete. In all cases authors should provide the same level of experimental detail and data (full details of requirements can be found in the “Journal Specific Guidelines” section below).

Research findings should be presented in an informative way, emphasising the importance and potential impact of the research. Authors should limit experimental procedures and data in the main text to a maximum two journal pages (approximately 5 double-spaced pages), with all additional experimental information and data placed in the electronic supplementary information (ESI).

Authors are particularly encouraged to prepare a title and abstract which concisely summarise the key findings of their research and their importance, avoiding the use of non-standard abbreviations, acronyms and symbols, as this will enable potential readers to quickly understand the significance of the research. Authors should also consider using recognisable, searchable terms, as around 70% of our readers come directly via search engines. The table of contents graphic should give the reader a clear indication of the topic of the study, for example by showing key compounds.

Authors are encouraged to use the article template, available from our  Author templates & services page , for preparing their submissions. However, the use of the template for Research article submissions is not essential.

Additional guidance on the layout and formatting of the article and supplementary information can be found on our  Prepare your article page .

Review article

These are easy-to-read articles covering current areas of interest for a broad medicinal chemistry audience. They are a concise and critical appraisal of an area in medicinal chemistry or a related topic, typically 6-12 pages in length. We also welcome shorter, mini-review style articles under this article type.

Reviews should focus on the key developments that have shaped the topic, rather than comprehensive reviews of the literature. Authors are encouraged to summarise important findings instead of re-iterating details already available in the primary work and should provide summary figures instead of multiple figures from original manuscripts, where appropriate.

Authors should include their own perspective on developments and trends, and the final paragraphs should discuss future directions, particularly identifying areas where further developments are imminent or that are in urgent need of being addressed.

Please note that Reviews should include balanced coverage of the field and not focus predominantly on the author’s own research.

Opinions are short, personal viewpoints on a topic of current interest to the community. They can be speculative in nature and stimulate counter-opinion, provided that they are not defamatory to the work of others. They should contain rigorous, evidence-backed scientific justification, and bring significant and valuable insights to the field.

Opinions are typically three to four pages in length and are normally published by invitation of the  RSC Medicinal Chemistry  Editorial Board or Editorial Office. Opinions undergo a rigorous and full peer review procedure, in the same way as Research and Review articles.

Comments and Replies are a medium for the discussion and exchange of scientific opinions between authors and readers concerning material published in  RSC Medicinal Chemistry .

For publication, a Comment should present an alternative analysis of and/or new insight into the previously published material. Any Reply should further the discussion presented in the original article and the Comment. Comments and Replies that contain any form of personal attack are not suitable for publication. 

Comments that are acceptable for publication will be forwarded to the authors of the work being discussed, and these authors will be given the opportunity to submit a Reply. The Comment and Reply will both be subject to rigorous peer review in consultation with the journal’s Editorial Board where appropriate. The Comment and Reply will be published together.

Journal specific guidelines

Human and animal welfare.

When a study involves the use of live animals or human subjects, authors must include in the 'methods/experimental' section of the manuscript a statement that all experiments were performed in compliance with the relevant laws and institutional guidelines, and must state the institutional committee(s) that has approved the experiments. A statement that informed consent was obtained for any experimentation with human subjects is required. Reviewers may be asked to comment specifically on any cases in which concerns arise.

More information on the Royal Society of Chemistry journals’ ethical policies can be found in our Author responsibilities page .

Disclosure of chemical structures

Chemical structures should be reported in the manuscript if that structure is necessary to understand the paper or repeat an experimental or computational procedure. Chemical structures should not be blanked out. In certain cases the non-disclosure of chemical structures may be acceptable, and these are considered on a case-by-case basis by the Associate Editor.

Experimental methods and data

Sufficient details of experimental or computational procedures should be included such that a scientist skilled in the art would be able to reproduce the results presented. The synthesis of all new compounds must be described in detail. Descriptions of synthetic procedures must include the specific reagents and solvents employed and must give the amounts (g, mmol) used. Products yields (%) must be reported together with a clear statement of how the percentage yields were calculated. The final physical state (solid; amorphous; liquid; solution) of the product should be disclosed. Where compounds are synthesised as part of an array or library a representative synthesis will be sufficient.

Authors should limit experimental procedures and data to two journal pages (approximately 5 double-spaced pages), with all additional experimental information and data placed in the electronic supplementary information (ESI).

Characterisation of organic compounds

Characterisation levels should be consistent with the importance of the compound to the conclusion of the work:

• For all tested compounds purity should be at least 95%, confirmed by either 1 H/ 13 C NMR data (with spectrum presented in the supplementary file), HPLC, GC, electrophoresis or elemental analysis. Further characterisation data should be supplied where available
• For key compounds (those which are subject to further study beyond initial screening), additional data should include 1 H NMR data (with spectrum presented in the supplementary file) and LC-MS data. Further data such as 13 C NMR, IR, CHN data and HRMS data should be supplied if available
• For chiral compounds, when used as a non-racemate, specific rotation and evidence of enantiomeric purity via chiral HPLC or derivatisation to diastereoisomeric compounds/use of chiral shift reagents should be given. Where HPLC is used conditions employed should be supplied including column type, flow rate, solvent system and detection method
• For compounds made as part of an array that are not considered key compounds, LC-MS data is sufficient.
• For compounds generated through combinatorial methods, lead compounds should be characterised to the same standards as compounds generated through standard synthetic procedures.
• For known compounds, an original reference to previously reported data should be cited; however authors should also include any new, previously unpublished characterisation data that have been obtained for known compounds.

Characterisation of biomolecules (For example, enzymes, peptides, proteins, DNA/RNA, oligosaccharides, oligonucleotides)

Authors should provide evidence for the identity and purity of the biomolecules described. The techniques that may be employed to substantiate identity include the following:

• Mass spectrometry
• Sequencing data (for proteins and oligonucleotides)
• High field 1 H, 13 C NMR
• X-ray crystallography

Purity must be established by one or more of the following:

• Gel electrophoresis
• Capillary electrophoresis
• High field 1 H, 13 C NMR.

Sequence verification should also be provided for nucleic acid cases involving molecular biology. For organic synthesis involving DNA, RNA oligonucleotides, their derivatives or mimics, purity must be established using HPLC and mass spectrometry as a minimum. For new derivatives comprising modified monomers, the usual organic chemistry analytical requirements for the novel monomer must be provided. However, it is not necessary to provide this level of characterisation for the oligonucleotide into which the novel monomer is incorporated.

Novel macromolecular structures and newly reported nucleic acid or protein sequences and microarray data must be deposited with the appropriate database. Articles will not be published until the relevant accession number has been provided. These codes should be quoted in the experimental section of the manuscript. Microarray data should be MIAME compliant.

All Western blot and other electrophoresis data should be supported by the underlying raw images. The image of the full gel and blot, uncropped and unprocessed, should be provided in the supplementary information on submission. All samples and controls used for a comparative analysis should be run on the same gel or blot.

When illustrating the result, any cropping or rearrangement of lanes within an image should be stated in the figure legend and with lane boundaries clearly delineated. Alterations should be kept to a minimum required for clarity.

Each image should be appropriately labelled, with closest molecular mass markers and lanes labelled. All details must be visible, over or underexposed gels and blots are not acceptable. Authors should be able to provide raw data for all replicate experiments upon request.

Biological data

Biological test methods should be described in sufficient detail such that a scientist skilled in the art would be able to reproduce the results presented. Forms of administration as well as physical states and formulations should be noted. Doses and concentrations should be expressed as molar quantities (for example, mol kg -1 , µmol kg -1 , M, µM). For those compounds found to be inactive, the highest concentration ( in vitro ) or dose level ( in vivo ) tested should be indicated. For in vivo studies vehicle information should be supplied.

Quantitative biological data are required for all test compounds. It is expected that all tested compounds would be 95% pure and shown to be so using standard methods. Active compounds from combinatorial syntheses should be re-synthesised and retested to verify biological activity. In these cases experimental procedures and characterisation data as described above should be provided. Known or standard compounds or drugs should be tested under the same experimental conditions for the purpose of comparison (as a positive control). Data may be presented in tabulated form or as graphs; extensive data for compounds should be presented in the electronic supplementary information. Authors should use a number of significant figures that is relevant to the accuracy of the data. Information about the error associated with biological data, for example standard deviation or SEM, should be provided along with the number of experimental determinations.

Pan Assay Interference (PAINS) Compounds

In cases where potential assay interference compounds (for example covalent modifiers, luminescent molecules, redox active compounds, metal chelators, membrane disruptors or unstable compounds which can decompose to form active compounds)are reported as being active, authors should provide evidence in the experimental section that this activity is genuine and is not due to an artefact. For more information about interference compounds see JB Baell and GA Holloway, J. Med. Chem. 2010, 53 , 2719-2740.

Computational studies

Details of the types of computational studies that are suitable for publication in RSC Medicinal Chemistry are given in the “Scope” section above.

Computational methods should be described in sufficient detail such that a scientist skilled in the art would be able to reproduce the results presented. Where computational studies are accompanied by experimental results (for example to validate a prediction) those experimental procedures and data should also be described in detail (see guidelines for experimental procedures above). Where an existing computational method is used authors should provide reasoning why this is appropriate for their study.

QSAR & QSPR studies

Studies which report new methodology or theory should be validated against at least one other common data set for which a study using another method has been published previously. Standard studies must be accompanied by new experimental data which tests their predictive power. To be considered for RSC Medicinal Chemistry  such studies should demonstrate significant potential to advance the field of medicinal chemistry. Any data or structures which are used to carry out a QSAR or QSPR study should either be made available as supplementary material, or be freely available elsewhere with a reference to the location included in the manuscript.

Statistical analysis

In articles where there is large-scale statistical analysis one of the named authors should be a statistician.

Guidelines on writing titles, abstracts & table of contents entry

The title, abstract and table of contents entry (graphical abstract) are the first parts of your manuscript that editors, referees and potential readers will see, and once published they play a major part in a researcher’s decision to read your article. Therefore it’s important that these clearly and concisely show the main findings of your research and why they are important.

The title should be short and straightforward to appeal to a general reader, but detailed enough to properly reflect the contents of the article.

• Keep it relatively short – between 8 and 15 words is ideal
• Use easily recognisable words and phrases that can be read quickly 
• Use general terms for compounds and procedures rather than specific nomenclature or very specialised terms
• Avoid using non-standard abbreviations and symbols
• Avoid using subjective terms such as “novel”
• Use keywords and familiar, searchable terms – these can increase the chances of your article appearing in search results. Around 70% of our readers come directly via search engines.

The abstract is a single paragraph which summarises the findings of your research. It will help readers to decide whether your article is of interest to them.

• The length can vary from 40 to 150 words, but it should always be concise and easy to read, with recognisable words and phrases.
• It should set out the objectives of the work, the key findings and why this research is important (compared to other research in its field).
• It should emphasise (but not overstate) the significance and potential impact of the research in your article.
• Avoid including detailed information on how the research was carried out. This should be described in the main part of the manuscript.
• Like your title, make sure you use familiar, searchable terms and keywords.

Table of contents entry

A table of contents entry (graphical abstract) is required, which should be submitted at the revision stage. This should include an eye-catching graphic and 1-2 sentence(s) of text to summarise the key findings of the article to the reader. It will appear in the table of contents and feeds – for example, RSS feeds.

The graphic should:

• Be simple, but informative.
• Capture the reader’s attention (the use of colour is encouraged).
• Include a structure, scheme, graph, drawing, photograph or combination that conveys the message of the article. Please note, complex schematics or spectra should be avoided.
• Be original, unpublished artwork created by one of the co-authors. Preferably, the graphic should not be reused and appear again within the article.
• Be suitable for, and uphold the standards of, a scholarly publication that has a global reach.
• Not contain any elements that are offensive or inappropriate, in particular words or images that are discriminatory.
• Not contain large amounts of text. Text should be limited to the labelling of compounds, reaction arrows and diagrams, with long phrases or sentences being avoided. Any text should be clearly legible to a reader.
• Not contain logos, trademarks or brands names.

The text should:

• Be concise and focus only on the key findings of the manuscript and their importance, not the processes used; think about what would grab the attention of the potential reader and would encourage them to read the full article.
• Avoid repeating or paraphrasing the title or abstract.
• Use easily recognisable words and phrases that can be read quickly.

Table of contents specifications:

• The figure should be a maximum size of 8 cm wide x 4 cm high.
• Figures should be supplied as TIFF files, with a resolution of 600 dpi or greater.
• The text supplied should be 1-2 sentences long, using a maximum of 250 characters.

Injectable peptide hydrogels for controlled-release of opioids From DOI:  10.1039/C5MD00440C

Drug trapping in hERG K +  channels: (not) a matter of drug size? From DOI:  10.1039/C5MD00443H

Structural hybridization of three aminoglycoside antibiotics yields a potent broad-spectrum bactericide that eludes bacterial resistance enzymes From DOI:  10.1039/C5MD00429B

Rigid amphipathic nucleosides suppress reproduction of the tick-borne encephalitis virus From DOI:  10.1039/C5MD00538H

Vast numbers of prevalent aminoglycoside-modifying enzymes undermine the clinical use of aminoglycoside antibiotics. We present the design and synthesis of a potent broad-spectrum bactericidal aminoglycoside based on available X-ray co-crystal structures within the ribosomal binding-site. The resulting antibiotic displays broad protection of its functional groups from inactivation by clinically relevant resistance enzymes.

From DOI:  10.1039/C5MD00429B

Advanced glycation end products (AGEs) are associated with various diseases, especially during aging and the development of diabetes and uremia. To better understand these biological processes, investigation of the in vivo kinetics of AGEs, i.e., analysis of trafficking and clearance properties, was carried out by molecular imaging. Following the preparation of Cy7.5-labeled AGE-albumin and intravenous injection in BALB/cA-nu/nu mice, noninvasive fluorescence kinetics analysis was performed. In vivo imaging and fluorescence microscopy analysis revealed that non-enzymatic AGEs were smoothly captured by scavenger cells in the liver, i.e., Kupffer and other sinusoidal cells, but were unable to be properly cleared from the body. Overall, these results highlight an important link between AGEs and various disorders

From DOI:  10.1039/C6OB00098C

A screen of 20 compounds identified small molecule adjuvants capable of potentiating antibiotic activity against  Francisella philomiragia . Analogue synthesis of an initial hit compound led to the discovery of a potentially new class of small molecule adjuvants containing an indole core. The lead compound was able to lower the MIC of colistin by 32-fold against intrinsically resistant  F. philomiragia .

From DOI:  10.1039/C5MD00353A

Table of contents

Structural modifications through bioisosteric approach yielded fusidic acid analogues with 2–35 folds increase in antiplasmodial activity as compared to fusidic acid. From DOI: 10.1039/C5MD00343A

The combination of flow chemistry and computational tools has been successfully applied to prepare a focused library of tricyclic tetrahydroquinolines endowed with drug-like properties. From DOI:  10.1039/C5MD00455A

A screen of 20 compounds identified small molecule adjuvants capable of potentiating antibiotic activity against  Francisella philomiragia . From DOI:  10.1039/C5MD00353A

A platinum complex/peptide chimera shows specific DNA binding and covalent platination with potential as a novel chemotherapeutic. From DOI:  10.1039/C5OB01885D

Open access publishing options

RSC Medicinal Chemistry  is a hybrid (transformative) journal and gives authors the choice of publishing their research either via the traditional subscription-based model or instead by choosing our gold open access option.  Find out more about our Transformative Journals. which are Plan S compliant .

Gold open access

For authors who want to publish their article gold open access , RSC Medicinal Chemistry  charges an article processing charge (APC) of £2,500 (+ any applicable tax). Our APC is all-inclusive and makes your article freely available online immediately, permanently, and includes your choice of Creative Commons licence (CC BY or CC BY-NC) at no extra cost. It is not a submission charge, so you only pay if your article is accepted for publication.

Learn more about publishing open access .

Read & Publish

If your institution has a Read & Publish agreement in place with the Royal Society of Chemistry, APCs for gold open access publishing in RSC Medicinal Chemistry  may already be covered.

Use our journal finder to check if your institution has an open access agreement with us.

Please use your official institutional email address to submit your manuscript and check you are assigned as the corresponding author; this helps us to identify if you are eligible for Read & Publish or other APC discounts.

Traditional subscription model

Authors can also publish in RSC Medicinal Chemistry via the traditional subscription model without needing to pay an APC. Articles published via this route are available to institutions and individuals who subscribe to the journal. Our standard licence allows you to make the accepted manuscript of your article freely available after a 12-month embargo period. This is known as the green route to open access.

Learn more about green open access .

Readership information

Researchers in academia and industry studying medicinal chemistry, pharmacology, and topics in the wider chemical, biological and materials sciences with application to biological problems.

Subscription information

RSC Medicinal Chemistry  is part of the RSC Gold subscription package.

Online only 2023 : ISSN 2632-8682, £1,643 / $2,435

*2022 Journal Citation Reports (Clarivate Analytics, 2023)

**The median time from submission to first decision including manuscripts rejected without peer review from the previous calendar year

***The median time from submission to first decision for peer-reviewed manuscripts rejected from the previous calendar year

****CiteScore™ 2022 available at   www.scopus.com/sources

Advertisement

Volumes and issues

Volume 32 january - august 2023.

• August 2023, issue 8

Special Issue in Honor of Dr. Nicholas A. Meanwell on the Occasion of His Retirement from Bristol Myers Squibb

• June 2023, issue 6
• May 2023, issue 5
• April 2023, issue 4
• March 2023, issue 3
• February 2023, issue 2
• January 2023, issue 1

Volume 31 January - December 2022

• December 2022, issue 12
• November 2022, issue 11

Special issue of Medicinal Chemistry Research in honor of Professor Edmond J. LaVoie

• September 2022, issue 9
• August 2022, issue 8

Special Issue in Honor of Prof. Laurence H. Hurley for His Many Contributions in Medicinal Chemistry and Drug Discovery

• June 2022, issue 6
• May 2022, issue 5
• April 2022, issue 4
• March 2022, issue 3
• February 2022, issue 2
• January 2022, issue 1

Volume 30 January - December 2021

• December 2021, issue 12
• November 2021, issue 11
• October 2021, issue 10
• September 2021, issue 9
• August 2021, issue 8

Special Issue in Honor of Professor Gary L. Grunewald for His Many Contributions and Years of Service to the Field of Medicinal Chemistry

• June 2021, issue 6
• May 2021, issue 5
• April 2021, issue 4
• March 2021, issue 3

Special Issue in Honor of Professor Robert Vince on the Occasion of his 80th Birthday

• January 2021, issue 1

Volume 29 January - December 2020

• December 2020, issue 12
• November 2020, issue 11
• October 2020, issue 10
• September 2020, issue 9
• August 2020, issue 8

Special Issue in Honor of Professor Robert P. Hanzlik on the Occasion of His Retirement

• June 2020, issue 6
• May 2020, issue 5
• April 2020, issue 4
• March 2020, issue 3
• February 2020, issue 2
• January 2020, issue 1

Volume 28 January - December 2019

• December 2019, issue 12
• November 2019, issue 11
• October 2019, issue 10
• September 2019, issue 9
• August 2019, issue 8
• July 2019, issue 7
• June 2019, issue 6
• May 2019, issue 5
• April 2019, issue 4
• March 2019, issue 3
• February 2019, issue 2
• January 2019, issue 1

Volume 27 January - December 2018

• December 2018, issue 11-12
• October 2018, issue 10
• September 2018, issue 9
• August 2018, issue 8
• July 2018, issue 7
• June 2018, issue 6
• May 2018, issue 5
• April 2018, issue 4
• March 2018, issue 3
• February 2018, issue 2
• January 2018, issue 1

Volume 26 January - December 2017

• December 2017, issue 12
• November 2017, issue 11
• October 2017, issue 10
• September 2017, issue 9
• August 2017, issue 8
• July 2017, issue 7
• June 2017, issue 6
• May 2017, issue 5
• April 2017, issue 4
• March 2017, issue 3
• February 2017, issue 2
• January 2017, issue 1

Volume 25 January - December 2016

• December 2016, issue 12
• November 2016, issue 11
• October 2016, issue 10
• September 2016, issue 9
• August 2016, issue 8
• July 2016, issue 7
• June 2016, issue 6
• May 2016, issue 5
• April 2016, issue 4
• March 2016, issue 3
• February 2016, issue 2
• January 2016, issue 1

Volume 24 January - December 2015

• December 2015, issue 12
• November 2015, issue 11
• October 2015, issue 10
• September 2015, issue 9
• August 2015, issue 8
• July 2015, issue 7
• June 2015, issue 6
• May 2015, issue 5
• April 2015, issue 4
• March 2015, issue 3
• February 2015, issue 2
• January 2015, issue 1

Volume 23 January - December 2014

• December 2014, issue 12
• November 2014, issue 11
• October 2014, issue 10
• September 2014, issue 9
• August 2014, issue 8
• July 2014, issue 7
• June 2014, issue 6
• May 2014, issue 5
• April 2014, issue 4
• March 2014, issue 3
• February 2014, issue 2
• January 2014, issue 1

Volume 22 January - December 2013

• December 2013, issue 12
• November 2013, issue 11
• October 2013, issue 10
• September 2013, issue 9
• August 2013, issue 8
• July 2013, issue 7
• June 2013, issue 6
• May 2013, issue 5
• April 2013, issue 4
• March 2013, issue 3
• February 2013, issue 2
• January 2013, issue 1

Volume 21 January - December 2012

• December 2012, issue 12
• November 2012, issue 11
• October 2012, issue 10
• September 2012, issue 9
• August 2012, issue 8
• July 2012, issue 7
• June 2012, issue 6
• May 2012, issue 5
• April 2012, issue 4
• March 2012, issue 3
• February 2012, issue 2
• January 2012, issue 1

Volume 20 January - December 2011

Special Issue: Current Trends In Drug Discovery Research; 17th-21st February, 2010 at Lucknow, India

• November 2011, issue 8
• September 2011, issue 7
• July 2011, issue 6
• June 2011, issue 5
• May 2011, issue 4
• April 2011, issue 3
• March 2011, issue 2
• January 2011, issue 1

Volume 19 February - December 2010

• December 2010, issue 9
• November 2010, issue 8
• September 2010, issue 7
• July 2010, issue 6
• June 2010, issue 5
• May 2010, issue 4
• April 2010, issue 3
• March 2010, issue 2
• February 2010, issue 1 This is a supplement
• February 2010, issue 1

Volume 18 February - December 2009

• December 2009, issue 9
• November 2009, issue 8
• September 2009, issue 7
• July 2009, issue 6
• June 2009, issue 5
• May 2009, issue 4
• March 2009, issue 3
• March 2009, issue 2
• February 2009, issue 1

Volume 17 April - December 2008

• December 2008, issue 9
• October 2008, issue 8
• June 2008, issue 2-7
• April 2008, issue 1

Volume 16 September 2007 - January 2008

• January 2008, issue 1
• December 2007, issue 7-9
• December 2007, issue 6
• December 2007, issue 5
• December 2007, issue 3
• December 2007, issue 2
• September 2007, issue 4

Volume 15 April 2006 - December 2007

• December 2007, issue 9
• August 2007, issue 7-8
• April 2006, issue 1-6

Volume 14 January - December 2005

• December 2005, issue 8-9
• October 2005, issue 7
• September 2005, issue 6
• July 2005, issue 5
• June 2005, issue 4
• April 2005, issue 3
• February 2005, issue 2
• January 2005, issue 1

Volume 13 January - October 2004

• October 2004, issue 8-9
• July 2004, issue 6-7
• June 2004, issue 5
• April 2004, issue 3-4
• January 2004, issue 1-2

For authors

Working on a manuscript.

Avoid the most common mistakes and prepare your manuscript for journal editors.

• Find a journal
• Publish with us

Current Topics in Medicinal Chemistry: The Six Most Cited Publications 2016-2019

Affiliation.

• 1 Fox Chase Chemical Diversity Center, Inc. (FCCDC) 3805 Old Easton Rd. Doylestown, PA 18902, United States.
• PMID: 31592749
• DOI: 10.2174/156802661917190828110645

Copyright© Bentham Science Publishers; For any queries, please email at [email protected].

Publication types

• Historical Article
• Anti-Bacterial Agents / pharmacology
• Antineoplastic Agents / pharmacology
• Chemistry, Pharmaceutical / history*
• Communicable Diseases / drug therapy
• Communicable Diseases / genetics
• Communicable Diseases / pathology
• History, 21st Century
• Neoplasms / drug therapy
• Neoplasms / genetics
• Neoplasms / pathology
• Research Report / history*
• Anti-Bacterial Agents
• Antineoplastic Agents

Call For Papers: a Special issue in honor of Dr. Nicholas A. Meanwell

We are delighted to announce this special issue of Med. Chem. Res. honoring Dr. Meanwell. This special issue will be guest edited by Drs. John Kadow, Murali Dhar, and Kap-Sun Yeung. We would like to invite you to submit a comment, review, brief report, or research article to this special issue under the broad theme of drug discovery.

We aim for submission by March 31, 2023, and publication of the special issue in summer 2023.

Dr. Nick Meanwell received his Ph.D. degree in organic chemistry with Dr. Neville Jones from the University of Sheffield, England in 1976 and did his postdoctoral research with Prof. Carl Johnson at Wayne State University. He joined Bristol Myers Squibb (BMS) in 1982, rose through the ranks, and became the Vice President, Discovery Chemistry Platforms at Bristol Myers Squibb Research and Early Development until his retirement in October 2022. During his forty-year tenure at BMS, Nick led many drug discovery programs across several therapeutic areas including cardiovascular, neurosciences, and virology. He and his teams advanced 33 clinical candidates for the prevention of thrombosis, the treatment of stroke, and therapy for viral infections that included HIV, HCV and RSV. Most notably, his work has resulted in the approval of several drugs including fostemsavir, a phosphonooxymethyl prodrug of temsavir, approved by the FDA on July 2, 2020, and marketed as Rukobia TM for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection; daclatasvir (Daklinza TM ), a pioneering molecule that established HCV NS5A inhibition as a clinically-relevant target; asunaprevir (Sunvepra TM ), an HCV NS3 protease inhibitor incorporating the cyclopropyl acylsulfonamide moiety that has been widely adopted; and beclabuvir, a thumb site inhibitor of HCV NS5B polymerase. Both daclatasvir and asunaprevir were marketed as a combination therapy for the treatment of HCV genotype 1b infection. In addition, beclabuvir was approved in Japan in December 2016 for the treatment of HCV genotype 1 infection as part of a fixed dose combination with daclatasvir and asunaprevir, marketed as Xymency TM . He has coauthored over 260 peer-reviewed articles and 25 book chapters, edited 2 books, and is an inventor of over 140 issued US patents. He has given over 200 presentations, seminars, lectures, short courses, and workshops. He has served in the editorial boards of a number of journals. Nick received many awards for his pioneering drug discovery work including being a co-recipient of a PhRMA Research and Hope Award for Biopharmaceutical Industry Research in 2014 for outstanding research in the area of HIV/AIDS; recipient of the  2015 Philip S. Portoghese Medicinal Chemistry Lectureship Award administered jointly by the ACS Division of Medicinal Chemistry and the Journal of Medicinal Chemistry , induction into the ACS Division of Medicinal Chemistry Hall of Fame in 2015; a co-recipient of a 2017 ACS “Heroes of Chemistry” Award; recipient of the 2022 ACS Alfred Burger Award in Medicinal Chemistry , and a 2022 ACS Fellow.

Commentaries, Review articles, Brief Reports, or Research Articles are all welcome. Please specify S.I.: Honoring Dr. Meanwell under the Additional Information/Questionnaire tab during submission

For authors

Working on a manuscript.

Avoid the most common mistakes and prepare your manuscript for journal editors.

• ACS Publications

ACS Publishing Center

Author guidelines.

Last updated: August 24, 2023

Manuscript Submission Requirements Checklist

Scope of the journal, manuscript types, submit with fast format, document templates and format, acceptable software, file designations, and tex/latex, cover letter, manuscript text components, supporting information, research data policy, data requirements, language and editing services, preparing graphics, figure and illustration services, prior publication policy, editorial policies, providing potential reviewer names, manuscript transfer, proofs via acs direct correct, publication date and patent dates, asap publication, post-publication policies, sharing your published article.

Please review the Editorial “Simplifying Submission Requirements for the Journal of Medicinal Chemistry” for an overview of recent changes.

MAJOR CHANGE:

The journal no longer requires the Author Submission Checklist for Articles and Drug Annotations. Submissions should be accompanied by a standard cover letter that should include the title of the manuscript, a short description of the research, and why it is appropriate for JMC . The letter should also contain the Journal purity statement (which should also be stated in the general experimental section of the manuscript) that “All compounds are >95% pure by HPLC analysis.” HPLC traces should be included for all compounds that have in vivo data described in the manuscript or, if no in vivo data, a representative number of HPLC traces of compounds described with in vitro data in the SAR tables (HPLC traces should be in the Supporting Information, SI). Alternatively, other methods of purity determination (e.g. elemental analysis) that were used need to be indicated. Authors may suggest Associate Editor(s) to handle your manuscript, however, due to manuscript workload, the desired Editor may not be assigned.  

The Journal of Medicinal Chemistry (Journal) invites original research contributions dealing with chemical-biological relationships. The primary objective of the Journal is to publish studies that contribute to an understanding of the relationship between molecular structure and biological activity or mode of action.

Some specific areas that are appropriate include the following.

• Design, synthesis, and biological evaluation of novel biologically active compounds, diagnostic agents, or labeled ligands employed as pharmacological tools.
• Molecular modifications of reported series that lead to a significantly improved understanding of their structure-activity relationships (SAR). Routine extensions of existing series that do not utilize novel chemical or biological approaches or do not add significantly to a basic understanding of the SAR of the series will normally not be considered for publication.
• Structural biological studies (X-ray, NMR, etc.) of relevant ligands and targets with the aim of investigating molecular recognition processes in the action of biologically active compounds.
• Molecular biological studies (e.g., site-directed mutagenesis) of macromolecular targets that lead to an improved understanding of molecular recognition.
• Computational studies that analyze the SAR of compound series of general interest and lead to experimental studies or analysis of other available chemical and/or biological data that substantially advance medicinal chemistry knowledge.
• Substantially novel computational chemistry methods with demonstrated utility for the identification, optimization, or target interaction analysis of bioactive molecules.
• Effect of molecular structure on the distribution, pharmacokinetics, and metabolic transformation of biologically active compounds. This may include design, synthesis, and evaluation of novel types of prodrugs.
• Novel methodology with broad application to medicinal chemistry, but only if the methods have been tested on relevant molecules.
• The Journal does not publish papers based on studies with crude extracts.

The Journal publishes 24 issues per year on the second and fourth Thursdays of each month.

Manuscripts can be submitted as Articles , Perspectives , or Drug Annotations .

• Articles are definitive, full accounts of significant studies.
• Perspectives are interpretive accounts on subjects of current interest to medicinal chemists. Perspectives differ from reviews, as they feature multiple “teaching moments” to inform and educate the community while providing an overview of an area or topic. This series is intended to be a forum for experts to present their perspectives on emerging or active areas of research that affect the practice of medicinal chemistry. Manuscripts are usually submitted at the invitation of the Perspectives Editor. However, experts are welcome to contact the Perspective Editor to ensure that a topic is suitable. Approval is recommended prior to submission. Additional information can be found here .
• Drug Annotations are reports of development candidates in phase I, II, and III clinical trials, as well as new approved drugs. These manuscripts should provide a description of the selected development candidate (including structure), target(s), mechanism of action, associated SARs, pre-clinical pharmacological properties and rationale for bringing the drug to clinical trial (for example, first-in-class or improvements over previous lead compounds). Reports on original research are also acceptable. Clinical data are highly desirable but not required. Authors are welcome to contact the Drug Annotations Editor to ensure that a topic is suitable. Approval is recommended prior to submission but is not required.
• Letters to the Editor are commentaries on previously published work from the journal, as well as on general issues that directly or indirectly impact medicinal chemistry research. Commentaries on previously published work should be submitted within 18 months of the ASAP publication date of the original material. The purpose of this manuscript type is to start a dialog between authors and should not be used to supplement prior publications with new data. The author(s) of the original material will be given an opportunity to reply. Letters to the Editor are typically not peer-reviewed, however, in cases where new data are presented, manuscripts may be sent out for peer review at the Editor’s discretion. Reviewing previously published examples of Letter to the Editors is strongly recommended.
• Viewpoint manuscripts are invited by the Editors. Viewpoint manuscripts are typically accompanied commentaries to Featured Article s.
• Featured Articles are selected by the Editors from accepted Articles .

Please note that Journal of Medicinal Chemistry no longer publishes Brief Articles .

While this document will provide basic information on how to prepare and submit the manuscript as well as other critical information about publishing, we also encourage authors to visit the ACS Publishing Center for additional information on everything that is needed to prepare (and review) manuscripts for ACS journals and partner journals, such as

• Mastering the Art of Scientific Publication , which shares editor tips about a variety of topics including making your paper scientifically effective, preparing excellent graphics, and writing cover letters.
• Resources on how to prepare and submit a manuscript to ACS Paragon Plus, ACS Publications’ manuscript submission and peer review environment, including details on selecting the applicable Journal Publishing Agreement .
• Sharing your research with the public through the ACS Publications open access program.
• ACS Reviewer Lab , a free online course covering best practices for peer review and related ethical considerations. 
• ACS Author Lab , a free online course that empowers authors to prepare and submit strong manuscripts, avoiding errors that could lead to delays in the publication process.
• ACS Inclusivity Style Guide , a guide that helps researchers communicate in ways that recognize and respect diversity in all its forms.

Manuscript Preparation

All ACS journals and partner journals have simplified their formatting requirements in favor of a streamlined and standardized format for an initial manuscript submission. Read more about the requirements and the benefits these serves authors and reviewers here .

Manuscripts submitted for initial consideration must adhere to these standards:

• Submissions must be complete with clearly identified standard sections used to report original research, free of annotations or highlights, and include all numbered and labeled components.
• Figures, charts, tables, schemes, and equations should be embedded in the text at the point of relevance. Separate graphics can be supplied later at revision, if necessary.
• When required by a journal's structure or length limitations, manuscript templates should be used.
• References can be provided in any style, but they must be complete, including titles. For information about the required components of different reference types, please refer to the  ACS Style Quick Guide .
• Supporting Information must be submitted as a separate file(s).

Templates for the Journal of Medicinal Chemistry are available below for Articles .   The template facilitates the peer review process by allowing authors to place artwork and tables close to the point where they are discussed within the text.

A Sample Manuscript  is available for reference on proper styling and construction of your manuscript.

• Microsoft Word 2011 Template for Macintosh
• Microsoft Word 2010 Template for Windows | README file [PDF]

General information on the preparation of manuscripts may also be found in the ACS Guide to Scholarly Communication .

See the list of Acceptable Software and appropriate File Designations to be sure your file types are compatible with ACS Paragon Plus. Information for manuscripts generated from TeX/LaTeX is also available.

The journal no longer requires the Author Submission Checklist for Articles and Drug Annotations. Submissions should be accompanied by a standard cover letter that should include the title of the manuscript, a short description of the research, and why it is appropriate for JMC . The letter should also contain the Journal purity statement (which should also be stated in the general experimental section of the manuscript) that “All compounds are >95% pure by HPLC analysis.” HPLC traces should be included for all compounds that have in vivo data described in the manuscript or, if no in vivo data, a representative number of HPLC traces of compounds described with in vitro data in the SAR tables (HPLC traces should be in the Supporting Information, SI). Alternatively, other methods of purity determination (e.g. elemental analysis) that were used need to be indicated. Authors may suggest Associate Editor(s) to handle your manuscript, however, due to manuscript workload, the desired Editor may not be assigned. 

A. General Considerations

Manuscripts should be kept to a minimum length. Authors should write in clear, concise English, employing an editing service if necessary. The responsibility for all aspects of manuscript preparation rests with the authors. Extensive changes or rewriting of the manuscript will not be undertaken by the Editors. Please see the ACS Guide to Scholarly Communication , which provides helpful information for communicating research.  

All text (including the title page, abstract, all sections of the body of the paper, figure captions, scheme or chart titles, and footnotes and references) and tables should be in one file.

Manuscripts that do not adhere to the guidelines may be returned to authors for correction.

1.   Articles . Article format can be single column, double-spaced or double column, single spaced including text, references, tables, and legends. This applies to figures, schemes, and tables as well as text. Manuscripts do not have page limitations but should be kept to a minimum length. A template is not required. The experimental procedures for all of the steps in the synthesis of all tested compounds must be included in the experimental section of the manuscript.

2. Perspectives. Perspectives can be single column, double-spaced or double column, single spaced including text, references, tables, and legends. This applies to figures, schemes, and tables as well as text. A template is not required. Manuscripts do not have the same headings as other manuscript types. Author(s) biographies of less than 125 words each should be placed immediately before the references.

• Perspectives are no more than 25 journal pages (100 double-spaced manuscript pages) and should not contain more than 180 references.
• Miniperspectives are no more than 8 journal pages (32 double-spaced manuscript pages) and should not contain more than 70 references.
• Award Perspectives page limits are flexible, but they should conform to other requirements stated for Perspectives or Miniperspectives .

3. Drug Annotations. Drug Annotations can be single column, double-spaced or double column, single spaced including text, references, tables and legends. This applies to figures, schemes, and tables as well as text. In general, manuscripts should include design and chemistry, known biological targets, in vitro and in vivo biological activity, pharmacological properties, and available toxicity information. Clinical data are highly desirable but not required.

4.  Viewpoint. Manuscripts are limited to 2000 words, including title page, abstract (~50 words), references, tables, and illustrations.

5. Nomenclature. It is the responsibility of the authors to provide correct nomenclature. Nomenclature should conform to current American usage. It is acceptable to use semisynthetic or generic names for certain specialized classes of compounds, such as steroids, peptides, carbohydrates, etc. In such a case, the name should conform to the generally accepted nomenclature conventions for the compound class. Chemical names for drugs are preferred. If these are not practical, generic names, or names approved by the U.S. Adopted Names Council or by the World Health Organization, may be used. Authors may find the following sources useful for recommended nomenclature:

• The ACS Guide to Scholarly Communication , which provides helpful information for communicating research.
• Enzyme Nomenclature ; Webb, E. C., Ed.; Academic Press: Orlando, 1992.
• IUPHAR database of receptors and ion channels ( http://www.guidetopharmacology.org/ ).

6. Compound Code Numbers. Code numbers (including peptides) assigned to a compound may be used as follows:

• Use is permitted but excessive use is discouraged. Authors are encouraged to assign bold Arabic numbers to compounds. If code number usage is cumbersome or detracts from the readability of the manuscript, editors may require the authors to limit usage by assigning bold Arabic numbers.
• Once in the manuscript title.
• Code numbers in the text must correspond to structures or, if used only once, the chemical name must be provided with the code number. Code numbers in the text referring to a previously published compound must have a citation to a publication or a patent on first appearance.

Compounds widely employed as research tools and recognized primarily by code numbers may be designated in the manuscript by code numbers without the above restrictions. Their chemical name or structure should be provided as above. Editors have the discretion of determining which code numbers are considered widely employed.

7.   Trademark Names. Trademark names for reagents or drugs must be used only in the experimental section. Perspectives may use trademark names once in the manuscript. Do not use trademark or service mark symbols.

8. Interference Compounds. Active compounds from any source must be examined for known classes of assay interference compounds and this analysis must be provided in the General Experimental section. Compounds shown to display misleading assay readouts by a variety of mechanisms include, but are not limited to, aggregation, redox activity, fluorescence, protein reactivity, singlet-oxygen quenching, the presence of impurities, membrane disruption, and their decomposition in assay buffer to form reactive compounds. Many of these compounds have been classified as Pan Assay Interference Compounds (PAINS; see Aldrich et al. J. Med. Chem. 2017, 60 , 2165-2168  and webinar at bit.ly/jmcPAINS ). Provide firm experimental evidence in at least two different assays that reported compounds with potential PAINS liability are specifically active and their apparent activity is not an artifact.

B. Manuscript Organization

Manuscripts can be submitted in a general double-column ACS template or as a general Word document, single-spaced. Please insert figures/tables/schemes, etc. in the text where they should be located based on text references  and  not at the end of the Word document . For chemical structures, ChemDraw with the ACS preferences selected is preferred; however, authors who do not have access to ChemDraw may use whichever available drawing program.

1.   Title Page. Title : The title of the manuscript is of great importance and should be constructed with care for readability and should reflect the purposes and findings of the work in order to provide maximum information in a computerized title search. Minimal use of nonfunctional words is encouraged. Only commonly employed abbreviations (e.g., DNA, RNA, ATP) are acceptable. Code numbers for compounds may be used in a manuscript title. Avoid complex compound names as much as possible in the title by using generic names or code numbers, and spell out elements rather than using symbols unless part of a compound name. Neither the title nor any other text should indicate that the paper is part of a numbered series on a broader research topic, or a numbered contribution from a particular institution or research group. IUPAC names are not required in the title and actually not preferred.

Code numbers for compounds may be used in a manuscript title when placed in parentheses AFTER the chemical or descriptive name.

Authors' Names and Affiliations : The authors' full first and last names and affiliations with addresses (including postal codes) at time of work completion should be listed below the title. The name of the corresponding author should be marked with an asterisk (*).

2.   Abstract. Articles , Drug Annotations, Perspectives , and Viewpoints must have an abstract following the title page. For Articles, Drug Annotations, and Perspectives, 150 words are usually adequate; for Viewpoints , 50 words are adequate. Abstracts should be presented in a findings-oriented format in which the most important results and conclusions are summarized. Descriptive names or code names may be used in the abstract.

3. Introduction. The rationale and objectives of the research should be discussed in this section. The background material should be brief and relevant to the research described.

4. Results. This section could include synthetic schemes and tables of biological data. The discussion of the chemistry and biology should be descriptive. Note that results and discussion may be combined with a separate conclusions section.

5. Discussion and Conclusions. Authors should discuss the analysis of the data together with the significance of results and conclusions, if a separate conclusions section is not employed.

6. Experimental Section. Authors should be as concise as possible in experimental descriptions. General reaction conditions should be given only once. The title of an experiment should be followed by the parenthesized code number or bold Arabic identifier number.

The Experimental section must include the purity statement “All compounds are >95% pure by HPLC.” HPLC traces should be included for representative compounds that have in vitro data and for all compounds with in vivo data described in the manuscript. Reasons for any exceptions/exclusions should be explained.

The experimental procedures for all of the steps in the synthesis of target compounds must be included in the experimental section of the manuscript and not in the SI.

Molar equivalents of all reactants and percentage yields of products should be included.

A general introductory section should include general procedures, standard techniques, and instruments employed (e.g., determination of purity, chromatography, NMR spectra, mass spectra, names of equipment) in the synthesis and characterization of compounds described subsequently in this section. Provide analysis for known classes of assay interference compounds.

Authors must emphasize any unexpected, new, and/or significant hazards or risks associated with the reported work. This information should be in the experimental details section of the manuscript.

Abbreviations. Standard abbreviations should be used throughout the experimental section (see Standard Abbreviations and Acronyms ). Please note that these are used in ACS Journals without periods. The preferred forms for some of the more commonly used abbrevations are mp, bp, ºC, K, min, h, mL, μL, g, mg, μg, cm, mm, nm, mol, mmol, μmol, ppm, TLC, GC, NMR, UV, and IR. Units are abbreviated in table column heads and when used with numbers, not otherwise. For further information, refer to The ACS Style Guide.

7. Ancillary Information. Include pertinent information in the order listed immediately before the references.

Supporting Information: Provide brief descriptions in non-sentence format listing the contents of the files supplied as Supporting Information.

PDB ID Codes : Include the PDB ID codes with assigned compound Arabic number. Include the statement “Authors will release the atomic coordinates and experimental data upon article publication.”

Homology Models: Coordinates of homology models in PDB format should be submitted as Supporting Information for Publication.

Corresponding Author Information: Provide email addresses for each of the designated corresponding authors.

Present/Current Author Addresses: Provide information for authors whose affiliations or addresses have changed.

Author Contributions:  Include a statement such as "These authors contributed equally."

Acknowledgment: Authors may acknowledge people, organizations, and financial supporters in this section.

Abbreviations Used: Provide a list of nonstandard abbreviations and acronyms used in the paper, e.g., "YFP, yellow fluorescent protein." Separate by semicolons.  Do not include compound code numbers in this list. It is not necessary to include abbreviations and acronyms from the Standard Abbreviations and Acronyms list.

8.   References and Notes. Number literature references and notes in one consecutive series by order of mention in the text. Footnotes are not used. Numbers in the text are non-parenthesized superscripts. The accuracy of the references is the responsibility of the corresponding author(s). Following are reference examples.

• Journals: Rich, D. H.; Green, J.; Toth, M. V.; Marshall, G. R.; Kent, S. B. H. Hydroxyethylamine Analogues of the p17/p24 Substrate Cleavage Site Are Tight-Binding Inhibitors of HIV Protease. J . Med . Chem . 1990 , 33 , 1285-1288.
• Online early access: Rubner, G.; Bensdorf, K.; Wellner, A.; Kircher, B.; Bergemann, S.; Ott, I.; Gust, R. Synthesis and Biological Activities of Transition Metal Complexes Based on Acetylsalicylic Acid as Neo-Anticancer Agents. J. Med. Chem. [Online early access]. DOI: 10.1021/jm101019j. Published Online: September 21, 2010. Note: If a citation is given, it should be provided in lieu of the DOI number.
• Periodicals published in electronic format only: Zloh, M.; Esposito, D.; Gibbons, W. A. Helical Net Plots and Lipid Favourable Surface Mapping of Transmembrane Helices of Integral Membrane Proteins: Aids to Structure Determination of Integral Member Proteins. Internet J. Chem. [Online] 2003, 6, Article 2. http://www.ijc.com/articles/2003v6/2/2/  (accessed Oct 13, 2004).
• Web Sites:  U. S. Environmental Protection Agency.  http://www.epa.gov  (accessed Nov 7, 2018).
• Edited Books: Rall, T. W.; Schleifer, L. S. Drugs Effective in the Therapy of the Epilepsies. In The Pharmacological Basis of Therapeutics , 7th ed.; Gilman, A. G., Goodman, L. S., Rall, T. W., Murad, F., Eds.; Macmillan: New York, 1985; pp 446-472.
• Patents:  Sheem, S. K. Low-Cost Fiber Optic Pressure Senor.  U.S. Patent 6,738,537, May 18, 2004 OR 2004. (Date format needs to be consistent.)

Excessive self-citations are discouraged.

List submitted manuscripts as “in press” only if formally accepted for publication. Manuscripts available on the Web with a DOI number are considered published. For manuscripts not accepted, use “unpublished results” after the names of authors.

Additional reference examples may be found on the Journal website .  

Prior to acceptance of a manuscript, journal citations must include:

• All authors; do not use 'et al.'
• Titles with capitalization of first word only (excluding, for example, acronyms and trade names) OR capitalization of first letter of all main words. The chosen style should be used consistently throughout the references. Note: This only pertains to Journals. All other publications should have initial capitalization of all main words.
• Inclusive complete starting and ending page numbers (e.g., 711-731 NOT 711-31).

9. Tables. Tabulation of experimental results is encouraged when this leads to more effective presentation or to more economical use of space. Tables should be numbered consecutively in order of citation in the text with Arabic numerals. Footnotes in tables should be given italic lowercase letter designations and cited in the tables as superscripts. The sequence of letters should proceed by row rather than by column. If a reference is cited in both table and text, insert a lettered footnote in the table to refer to the numbered reference in the text. Each table must be provided with a descriptive title that, together with column headings, should make the table self- explanatory.

Titles and footnotes should be on the same page as the table. Tables may be created using a word program text mode or table format feature. The table format feature is preferred. Ensure each data entry is in its own table cell. If the text mode is used, separate columns with a single tab and use a return at the end of each row. Tables should be inserted in the text where first mentioned.

10.   Image Manipulation. According to ACS Ethical Guidelines, images should be free from misleading manipulation. Images included in an account of research performed or in the data collection as part of the research require an accurate description of how the images were generated and produced. Apply digital processing uniformly to images, with both samples and controls. Cropping must be reported in the figure legend. For gels and blots, use of positive and negative controls is highly recommended. Avoid high contrast settings to avoid overexposure of gels and blots. For microscopy, apply color adjustment to entire image and note in the legend. When necessary, authors should include a section on equipment and settings in supporting information to describe all image acquisition tools, techniques and settings, and software used. All final images must have resolutions of 300 dpi or higher. Authors should retain unprocessed data in the event that the Editors request them. Unprocessed data can also be part of the supporting information.

11. Table of Contents Graphic. A graphic entry for the table of contents (TOC) must be supplied as the last page of the manuscript and labeled “Table of Contents graphic.” This small graphic should capture the reader's attention and, in conjunction with the manuscript title, should give the reader an idea of the key target compounds or series discussed in the paper. The TOC graphic will also appear in the abstract of the published PDF file. Do not provide a separate abstract graphic.

• A chemical structure should be clearly depicted.
• The TOC graphic should be entirely original work created by one of the coauthors and should not be a duplicate of a graphic appearing elsewhere in the manuscript.
• The TOC graphic should be no wider than 3.25 inches by 1.75 inches (approximately 8.25 cm by 4.45 cm).

For additional information see the ACS Publications Guidelines for Table of Contents/Abstract Graphics . 

12.   Molecular Formula Strings. Authors are required to submit SMILES  string computer- readable identifiers of molecules discussed in the manuscript along with the associated biochemical and biological data, if applicable as Supporting Information for Publication. It is recognized that some molecules, including antibodies, peptides greater than six amino acids, proteins, etc., do not contribute to the spirit of molecular formula strings and are exempt from this requirement. Judgment regarding exemption of ligands are at the discretion of the Editors. Submission of molecular formula strings and associated data enables enhanced quality control at review and can increase an article's discoverability and citability.

Getting started:

• Creating a Molecular Formula Strings Spreadsheet
• Molecular Formula Strings Template
• Example SMILES Document
• Announcing the use of SMILES in J Med Chem

Learn more about SMILES from Dr. Michael Gilson in Digital Chemistry in the Journal of Medicinal Chemistry  or watch the video .

Instructions for Authors:

• Use your existing chemical drawing programs (e.g., ChemDraw, ACD ChemSketch, Marvin Sketch) to generate a computer-readable SMILES formula for each compound presented in your article.
• Paste these formulas into the spreadsheet template, along with basic information about each compound. This spreadsheet will provide a machine-readable version of the key data presented in the article's tables.
• Upload the final CSV document in ACS Paragon Plus at the time of manuscript submission as Supporting Information for Publication.

13. Supporting Information. Authors are encouraged to make use of this resource when manuscripts contain extensive tabulations of data that are of interest only to those readers who may need more complete data.

The first page of the supporting information file should contain the title of the manuscript, the names of all authors, and a table of contents including page numbers; label this page “Supporting Information”. The pages must be consecutively numbered S1 (the title page), S2, etc. Figure captions, titles to tables, and other identifying captions should appear on the same page as the figures or tables. Supporting information may be single-spaced. Generally, if one has difficulty reading the material as submitted, it is unacceptable.

All supporting information files of the same type should be prepared as a single file (rather than submitting a series of files containing individual images or structures with the exception of PDB files for computational models). For example, all supporting information available as PDF files should be contained in one PDF file. Author-created file names will be automatically replaced with standardized file names generated at the time of publication.

DO NOT UPLOAD FIGURES AND TABLES THAT ARE TO BE PUBLISHED IN THE MANUSCRIPT AS SUPPORTING INFORMATION FILES .

This information is provided to the reviewers during the peer-review process (for Review Only) and is available to readers of the published work (for Publication). Supporting Information must be submitted at the same time as the manuscript. See the list of Acceptable Software by File Designation and confirm that your Supporting Information is viewable .

If the manuscript is accompanied by any supporting information files for publication, these files will be made available free of charge to readers. A brief, nonsentence description of the actual contents of each file, including the file type extension, is required. This description should be labeled Supporting Information and should appear before the Acknowledgement and Reference sections.  Examples of sufficient and insufficient descriptions are as follows:

Examples of sufficient descriptions: “Supporting Information: 1 H NMR spectra for all compounds (PDF)” or “Additional experimental details, materials, and methods, including photographs of experimental setup (DOC)”.

Examples of insufficient descriptions: “Supporting Information: Figures S1-S3” or “Additional figures as mentioned in the text”.

When including supporting information for review only, include copies of references that are unpublished or in-press. These files are available only to editors and reviewers.

All ACS journals strongly encourage authors to make the research data underlying their articles publicly available at the time of publication.

Research data is defined as materials and information used in the experiments that enable the validation of the conclusions drawn in the article, including primary data produced by the authors for the study being reported, secondary data reused or analyzed by the authors for the study, and any other materials necessary to reproduce or replicate the results.

The ACS Research Data Policy provides additional information on Data Availability Statements, Data Citation, and Data Repositories.

1. Biological Data. Quantitative biological data are required for all tested compounds. Biological test methods must be referenced or described in sufficient detail to permit the experiments to be repeated by others. Detailed descriptions of biological methods should be placed in the experimental section. Required information includes the source (if purchased or lab from which originally obtained, if applicable), description of cell line used (e.g., HEK293, COS-1, COS-7), etc., and experimental conditions necessary for those trained in the art to reproduce the experiments as detailed in the manuscript and under identical conditions. Standard compounds or established drugs should be tested in the same system for comparison. Data may be presented as numerical expressions or in graphical form; biological data for extensive series of compounds should be presented in tabular form. Significant figures should be appropriate for the data presented. Tables consisting primarily of negative data will not usually be accepted; however, for purposes of documentation they may be submitted as Supporting Information for Publication. Clearly state in the experimental section how many replicates and independent experiments were performed for the tested compounds to generate the biological data presented.

Active tested compounds obtained from combinatorial syntheses should be resynthesized, analytically characterized, and percent purity determined (with values provided) and retested in the biological assay to verify that the biology conforms to the initial observation. To increase the scientific rigor of the finding and the manuscript's contribution to the field, conformation in an orthogonal assay of the lead molecule(s) biological activity are highly encouraged. Judgment regarding if an orthogonal experiment is critical to the significance of the research presented are at the discretion of the Editors.

Statistical limits (statistical significance) for the biological data are usually required. If statistical limits cannot be provided, the number of determinations and some indication of the variability and reliability of the results should be given. References to statistical methods of calculation should be included. Concentrations should be expressed as molar quantities (e.g., mM, nM) and doses in animals should be expressed in weight/weight or molar quantities (e.g., mg/kg, mmol/kg). The routes of administration of test compounds and vehicles used should be indicated, and any salt forms used (hydrochlorides, sulfates, etc.) should be noted. The physical state of the compound dosed (crystalline, amorphous; solution, suspension) and the formulation for dosing (micronized, jet-milled, nanoparticles) should be indicated. For those compounds found to be inactive, the highest concentration (in vitro) or dose level (in vivo) tested should be indicated. See section 8 below on Statistical Criteria for more detailed requirements.

Cytotoxicity mean graphs from the National Cancer Institute (NCI) should appear in Supporting Information for Publication and not in the main body of the manuscript. Numerical data derived from a limited number of cell lines may be tabulated in the text of the manuscript.

If human cell lines are used, authors are strongly encouraged to include the following information in their manuscript in accordance with NIH guidelines:

• the cell line source, including when and from where it was obtained;
• whether the cell line has recently been authenticated and by what method;
• whether the cell line has recently been tested for mycoplasma contamination.

2. Use of Human or Animal Subjects . Manuscripts must comply with the ACS Ethical Guidelines to Publication of Chemical Research .   Sufficient information must be provided so that results can be reproduced and tested by other laboratories. For research involving animals or humans, Editors reserve the right to request additional information from authors.

Animals: Research involving animals must be performed in accordance with institutional guidelines as defined by Institutional Animal Care and Use Committee for U.S. institutions or an equivalent regulatory committee in other countries.

A statement confirming that all animal experiments performed in the manuscript were conducted in compliance with these guidelines is required. In the experimental section, the source, age, sex, species, and strain of animals should be included. For each treatment group, the number of animals used and sex should be clearly stated. Appropriate statistical methods should be used to test the "significance" of differences in results, and claims thereof. The term "significant" should not be used unless the appropriate statistical analysis was performed and the probability value (p- value) used to identify significance (generally p<0.05) is consistent with the scientific rigor of the field. Authors are encouraged to include in all figure and table captions the number of animals and sex for each treatment group, the method of statistical analysis as well as the corresponding p-values where significant differences are found.

Humans : Research studies involving humans must have institutional review board approval. Authors are requested to identify the institutional or licensing committee that has approved the experiments.

3. Purity of Tested Compounds.

Methods: All scientifically established methods (e.g., HPLC, combustion analysis, absolute quantitative 1 H NMR [qHNMR; see Purity by Absolute qNMR instructions ] following the established Journal protocol or equivalent qHNMR methods) of establishing purity are acceptable. Documentation is required for qHNMR. If the target compounds are solvated, the quantity of solvent should be included in the compound formulas. When HPLC is the method for determination of compound purity, HPLC traces are required only for key target compounds. Documentation is required to be uploaded as Supporting Information for Publication.

Purity Percentage: All tested compounds, whether synthesized or purchased, should possess a purity of at least 95%. Tested compounds must have a purity of at least 95%. In exceptional cases, authors can request a waiver when compounds are less than 95% pure. For solids, the melting point or melting point range should be reported as an indicator of purity.

Elemental analysis: Found values for carbon, hydrogen, and nitrogen (if present) should be within 0.4% of the calculated values for the proposed formula.

Statements/Documentation: Include the specific analytical method used to determine purity in the general part of the experimental section together with a statement confirming 95% purity. If the purity of a particular compound is less than 95%, specify the percentage of purity at the end of the description of its synthesis in the experimental section. For qHNMR experiments, additional documentation is required. For purchased compounds, provide proof of purchase as Supporting Information for Publication.

Cover Letter: The letter should contain the Journal purity statement (which should also be stated in the general experimental section of the manuscript) that “All compounds are >95% pure by HPLC analysis.” HPLC traces should be included for all compounds that have in vivo data described in the manuscript or, if no in vivo data, a representative number of HPLC traces of compounds described with in vitro data in the SAR tables (HPLC traces should be in the Supporting Information, SI). Alternatively, other methods of purity determination (e.g. elemental analysis) that were used need to be indicated.

4. Confirmation of Structure. Adequate evidence to establish structural identity must accompany all new compounds that appear in the experimental section of Articles and Drug Annotations . Sufficient spectral data should be presented in the experimental section to allow for the identification of the same compound by comparison. Generally, a listing of 1 H or 13 C NMR peaks is sufficient. However, when the NMR data are used as a basis of structural identification, the peaks must be assigned. Proton NMR shifts, reported to 0.01 ppm precision, should be accompanied by an abbreviation for any multiplet structure, the number of atoms represented by the peak or multiplet, and coupling constraints where applicable. J values are in hertz (Hz) and have one decimal place. Give 13C chemical shifts to one digit after the decimal point, unless an additional digit will help distinguish overlapping peaks. See  NMR Guidelines for ACS Journals .

List only infrared absorptions that are diagnostic for key functional groups. If a series contains very closely related compounds, it may be appropriate merely to list the spectral data for a single representative member when they share a common major structural component that has identical or very similar spectral features. HRMS data may be supplied as an additional criterion of compound identity. For the first member of a new class of oligomers containing up to 10 residues, 1 H NMR (300-500 MHz) and HRMS are a requirement.

Specific optical rotations should be reported for isolated natural products, enantiopure compounds, and enantioenriched isomer mixtures when sufficient sample is available. Specific rotations based on the equation [α] = (100α)/( lc ) should be reported as unitless numbers as in the following example: [α] 20 D 25 ( c 1.9, CHCl 3 ), where the concentration c is in g/l00 mL and the path length l is in decimeters. The units of the specific rotation, (deg*mL)/(g*dm), are implicit and are not included with the reported value.

5. Combinatorial Chemistry. When combinatorial chemistry has been employed to generate molecules, which become prototypes for a subsequent focused SAR investigation, the lead compounds and any other compounds that are key to the analysis and interpretation of the SAR of the focused series must conform to the appropriate criteria for purity and structural identity required by this Journal. However, the combinatorial chemistry methodology, screening data, and preliminary SAR which led to the generation of the lead molecule(s) may be reported as Supporting Information for Publication without confirmation of structure or demonstration of purity. These data may be briefly summarized in the main manuscript when they clarify the SAR discussion of the focused series.

6. Computational Chemistry.

6.1 Manuscript Categories . When computational chemistry is a major component of a study, manuscripts must fall into one or more of the following categories:

(A) Practical applications of existing computational methods combined with original experimental data. Manuscripts that report prospective computational design, synthesis, and experimental evaluation of new chemical entities are highly encouraged.

Applications of existing computational methods are not considered without original experimental data that assess the computational predictions. QSAR modeling is acceptable only if a significant number of new compounds is predicted, prepared, and tested. Avoid overinterpretation of computational predictions and conclusions drawn from molecular models as if they represent experimental data.

(B) Substantially novel methods along with evidence for utility in medicinal chemistry with significant potential for advancing the field.

Clearly describe computational methods to be accessible to a general medicinal chemistry audience and clarify the relevance of the new method to medicinal chemistry. Present sufficient information to allow the method to be reproduced and tested in other laboratories.

(C) Statistical analysis or mining of publicly available databases or data sets that provide unprecedented insights into the advancement of medicinal chemistry problems.

Such investigations must be based upon large data sets. Small series of compounds whose properties are reinvestigated using computational methods do not qualify for this category.

6.2 Proprietary Data . Normally, the use of proprietary data for computational modeling or analysis is not acceptable because it is inconsistent with the ACS Ethical Guidelines. All experimental data and molecular structures used to generate and/or validate computational models must be reported in the paper, reported as supporting information, or readily available without infringements or restrictions. The Editors may choose to waive the data deposition requirement for proprietary data in rare cases where studies based on large corporate data sets provide compelling insight unobtainable otherwise.

6.3 Virtual Screening Studies . Prospective virtual screen studies must meet the following acceptance criteria.

• In order to validate virtual screening hits obtained from any source, provide proof of dose-response behavior, confirmation of IC 50 or K i values, and controls for nonspecific or artificial inhibition (i.e., proof of reversibility, detergent controls). Submit structure confirmation ( 1 H NMR and MS; see section 4) for active compounds.
• For target-directed virtual screens, evidence for direct binding/inhibition must be provided; the exclusive use of cell-based/functional/reporter gene assays is insufficient.
• Include explicit support for the significance of experimental findings. Identifying weakly potent compounds for a given target is not considered a significant advance if many potent compounds acting by the same or a similar mechanism are already available.
• Virtual screening hits must be filtered for Pan Assay Interference Compounds (PAINS; Baell and Holloway, J. Med. Chem. 2010, 53, 2719-2740) and the results must be reported in the manuscript (exemplary online filter:  http://zinc15.docking.org/patterns/home/ ).
• For virtual screens that produce compound rankings, provide as Supporting Information for Publication the total number of compounds that were screened and the ranks of identified hits before application of any further manual or other subjective selection steps.
• Complex virtual screening protocols are not validated by identifying a few active compounds. Evidence must be provided that much simpler approaches would not have yielded comparable results (e.g., 2D similarity or substructure searching).
• Reported calculations must be limited to those that were essential for the identification of novel active compounds. In virtual screening studies, retrospective computational studies such as benchmarking or similar in silico validation attempts should not be reported. All computational studies that do not directly contribute to the identification of novel active compounds must be omitted.
• For virtual screening studies, computational models of targets (e.g. homology models) and ligand/target complexes such as docked/modeled complexes of active compounds must be made freely available as PDB coordinate files as Supporting Information for Publication (see also 6.7).

6.4 Retrospective Use of Computational Methods . Manuscripts that contain experimental studies with a retrospective computational component will be considered only under the following conditions:

• Computational work must lead to a clearly stated message, either an improved understanding of the experimental work or a well-defined experimentally testable hypothesis.
• Clearly distinguish models and hypothetical statements from experimental observations both in the text and in figure captions.
• Describe computational methods in sufficient detail for the reader to reproduce the results.
• Draw conclusions from modeling with an appropriate amount of caution in light of assumptions made and within the accuracy limitations of the applied computational methods. The overall amount of space (text and figures) devoted to retrospective computational work must be proportionate to its significance.

6.5 Predicted Compound Binding Modes . The prediction of compound binding modes by docking is a frequent computational application submitted to the Journal in combination with experimental data. Provide PBD IDs of crystal structures used as starting points for molecular modeling in the legends of figures depicting the resulting molecular models. In the absence of supporting structural information demonstrate that putative binding modes are consistent with structure-activity relationships for a series of analogues.

QSAR, pseudo-receptor, or machine learning models that are occasionally applied retrospectively to analyze biological activities observed in the context of experimental SAR studies are acceptable only when used to illustrate a point of central relevance for a manuscript.

6.6 Benchmark Calculations . Benchmark investigations, such as comparisons of virtual screening algorithms, are considered only if they provide particularly clear and generally relevant conclusions that set new standards in the field. General relevance and new standards must be clearly stated.

6.7 PDB Coordinates for Computational Models . If three-dimensional computational models of targets, binding sites, or target-ligand complexes are reported, PDB coordinates of hydrogen-suppressed atomic models must be included as Supporting Information for Publication at submission to ensure reproducibility of calculations and reported findings.

7. QSAR/QSPR and Proprietary Data. The following are general requirements for manuscripts reporting work done in this area:

• Authors should explicitly state in the abstract, introduction, and/or results sections of the paper what is novel about the quantitative structure–activity relationships/quantitative structure–property relationships (QSAR/QSPR) study being reported.
• If a new method/theory is reported, it should be compared to and “validated” against at least one other common method that is widely used in the field.
•    All data and molecular structures used to carry out a QSAR/QSPR study are to be reported in the paper and/or as Supporting Information for Publication. The use of proprietary data is generally not acceptable.
• Standard QSAR/QSPR studies are considered only if the predictions are experimentally tested and if the experimental data are novel and significant. Only QSAR/QSPR analyses that provide new insights into the activity are considered.

Specifically discouraged are (i) QSAR and QSPR modeling for data sets that have already been extensively modeled, (ii) model development featuring high ratios of descriptors to data points, and (iii) reports of new descriptors without clear evidence for their superiority in QSAR/QSPR modeling to existing, commonly used alternatives.

8. Statistical Criteria. Appropriate statistical assessment is equally important for experimental and computational studies in medicinal chemistry. Reported results generally require statistical validation such as the use of the probability value (p-value) used to identify significance (generally p < 0.05).  Statistical analyses of compound data are also frequently presented, which must adhere to acceptable statistical and scientific standards. Specifically:

• A clear and comprehensive description of experimental data or computed data underlying the analysis is required.
• Statistical methods used must be clearly identified. Non-standard statistical methods should be described in sufficient detail or precisely referenced.
• Underlying assumptions of statistical methods should be specified. For example, many statistical tests assume the presence of normal data distributions, which is often an approximation in practice.
• Depending on the type of experiments reported, either confidence limits (CL), standard deviations (SD), or standard errors of the mean (SEM) must accompany a mean value provided in either graphical or tabular form. The experimental section for each in vitro and in vivo assay performed should indicate the number of independent experiments as well as the statistical method used for data analysis. For example, assay curves must contain errors bars derived from multiple measurements.
• For regression curves, their uncertainty must be assessed by plotting the original data along the curve or by establishing experimental or calculation confidence limits.
• If average values are reported from computational analysis, their variance must be documented. This can be accomplished by providing the number of times calculations have been repeated, mean values, and standard deviations (or standard errors). Alternatively, median values and percentile ranges can be provided. Data might also be summarized in scatter plots or box plots.
• Reporting averages of data assigned to pre-defined value ranges and ‘averages of average values’ must be avoided.

9. Software. Software used as a part of computer-aided drug design should be readily available from reliable sources, and the authors should specify where the software can be obtained.

10. Structural Data. For papers describing structures of biological macromolecules, the atomic coordinates and the related experimental data (structure factor amplitudes/intensities and/or NMR restraints) must be deposited at a member site of the Worldwide Protein Data Bank ( www.wwpdb.org ): RCSB PDB ( www.pdb.org ), Protein Databank in Europe (PDBe) ( http://www.ebi.ac.uk/pdbe/docs/References.html ), PDBj ( www.pdbj.org ), or BMRB ( www.bmrb.wisc.edu ). The PDB ID must appear before the references (under Manuscript Text Components see section B.7) and in the figure legend. Authors must release the atomic coordinates and experimental data when the associated article is published. Questions related to deposits should be sent to [email protected] . Papers that utilize coordinates of molecules already in the database should specify the PDB ID as a reference.

For X-ray diffraction of structures of small molecules with anisotropically refined atoms, a figure displaying the thermal ellipsoids should ordinarily be presented; a spherical-atom representation may be substituted if necessary for clarity. If a spherical atom view is chosen for the manuscript, a thermal ellipsoid figure should be included in the supporting information. In cases where intermolecular interactions are relevant to the discussion, a view of the unit cell may be included. Articles should list for each structure the formula, formula weight, crystal system, space group, unit cell parameters, temperature of data collection, and values of Z , R , and GOF in the experimental section. Tables of atom coordinates and thermal parameters will not be printed. CIF files must be deposited with Cambridge Crystallographic Data Centre (CCDC).

11. Compound Characterization Checklist. When manuscripts report the synthesis of compounds, submission of a completed Compound Characterization Checklist (CCC) is recommended but not required . The CCC form  can be completed on-screen and saved for uploading with the submission of the manuscript as Supporting Information for Review Only. The CCC will be provided to reviewers to help them assess the overall thoroughness of the characterization of synthesized compounds.

A well-written paper helps share your results most clearly. ACS Publications’ English Editing Service is designed to help scientists communicate their research effectively. Our subject-matter expert editors will edit your manuscript for grammar, spelling, and other language errors so your ideas are presented at their best.

The quality of illustrations in ACS journals and partner journals depends on the quality of the original files provided by the authors. Figures are not modified or enhanced by journal production staff. All graphics must be prepared and submitted in digital format.

Graphics should be inserted into the main body whenever possible. Please see Appendix 2 for additional information.

Any graphic (figure chart, scheme, or equation) that has appeared in an earlier publication should include a credit line citing the original source. Authors are responsible for obtaining written permission to re-use this material.

The impact of your research is not limited to what you can express with words. Tables and figures such as graphs, photographs, illustrations, diagrams, and other visuals can play a significant role in effectively communicating your findings. Our Artwork Editing and Graphical Abstract services generate publication-ready figures and Table of Contents (TOC) graphics that conform to your chosen journal’s specifications. For figures, this includes changes to file type, resolution, color space, font, scale, line weights, and layout (to improve readability and professional appearance). For TOC graphics, our illustrators can work with a rough sketch or concept or help extract the key findings of your manuscript directly for use as a visual summary of your paper.

Preparing for Submission

Manuscripts, graphics, supporting information, and required forms, as well as manuscript revisions, must all be submitted in digital format through ACS Paragon Plus , which requires an ACS ID to log in. Registering for an ACS ID is fast, free, and does not require an ACS membership. Please refer to Appendix 1 for additional information on preparing your submission

Authors should submit only original work that has not been previously published and is not under consideration for publication elsewhere. Authors must note any use of a preprint server, patents, and dissertations in the cover letter. The following does not constitute prior publication:

• Academic theses, including those on the Web or at a college Web site.
• Preprint servers. Upon publication in the Journal, authors are advised to add a link in the preprint to the published paper via the Digital Object Identified (DOI).

Revisions: Articles , Perspectives , and Drug Annotations revisions must be submitted within seven days of a formatting only revision request, 30 days of a minor revision request, 60 days of a major revision request, and 180 days of a Reject & Resubmit request.

Please suggest 5 reviewers. Authors are encouraged to avoid suggesting reviewers from the authors’ institutions. Do not suggest reviewers who may have a real or perceived conflict of interest . Whenever possible, suggest academic email addresses rather than personal email addresses.

If your submission is declined for publication by this journal, the editors might deem your work to be better suited for another ACS Publications journal or partner journal and suggest that the authors consider transferring the submission. Manuscript Transfer simplifies and shortens the process of submitting to another ACS journal or partner journal, as all the coauthors, suggested reviewers, manuscript files, and responses to submission questions are copied by ACS Paragon Plus to the new draft submission. Authors are free to accept or decline the transfer offer.

Note that each journal is editorially independent. Transferring a manuscript is not a guarantee that the manuscript will be accepted, as the final publication decision will belong to the editor of the next journal.

PRODUCTION AND PUBLICATION

Correction of the galley proofs is the responsibility of the Corresponding Author. The Corresponding Author of an accepted manuscript will receive e-mail notification and complete instructions when page proofs are available for review via ACS Direct Correct . Extensive or important changes on page proofs, including changes to the title or list of authors, are subject to review by the editor.

It is the responsibility of the Corresponding Author to ensure that all authors listed on the manuscript agree with the changes made on the proofs. Galley proofs should be returned within 48 hours in order to ensure timely publication of the manuscript.

Accepted manuscripts will be published on the ACS Publications Web site as soon as page proofs are corrected and all author concerns are resolved. The first date on which the document is published on the Web is considered the publication date.

Publication of manuscripts on the Web may occur weeks in advance of the cover date of the issue of publication. Authors should take this into account when planning their patent and intellectual property activities related to a document and should ensure that all patent information is available at the time of first publication, whether ASAP or issue publication.

All articles published ahead of print receive a unique Digital Object Identifier (DOI) number, which is used to cite the manuscript before and after the paper appears in an issue. Additionally, any supplemental information submitted along with the manuscript will automatically be assigned a DOI and hosted on Figshare to promote open data discoverability and use of your research outputs.

Manuscripts will be published on the “ASAP Articles” page on the web as soon as page proofs are corrected and all author concerns are resolved. ASAP publication usually occurs within a few working days of receipt of page proof corrections, which can be several weeks in advance of the cover date of the issue.

The American Chemical Society follows guidance from the Committee on Publication Ethics (COPE) when considering any ethical concerns regarding a published article, Retractions, and Expressions of Concern.

Additions and Corrections

Additions and Corrections may be requested by the author(s) or initiated by the Editor to address important issues or correct errors and omissions of consequence that arise after publication of an article. All Additions and Corrections are subject to approval by the Editor, and should bring new and directly relevant information and corrections that fix scientific facts. Minor corrections and additions will not be published. Readers who detect errors of consequence in the work of others should contact the corresponding author of that work.

Additions and Corrections must be submitted as new manuscripts via ACS Paragon Plus by the Corresponding Author for publication in the “Addition/Correction” section of the Journal. The corresponding author should obtain approval from all coauthors prior to submitting or provide evidence that such approval has been solicited. The manuscript should include the original article title and author list, citation including DOI, and details of the correction.

Retractions

Articles may be retracted for scientific or ethical reasons and may be requested by the article author(s) or by the journal Editor(s), but are ultimately published at the discretion of the Editor. Articles that contain seriously flawed or erroneous data such that their findings and conclusions cannot be relied upon may be retracted in order to correct the scientific record. When an article is retracted, a notice of Retraction will be published containing information about the reason for the Retraction. The originally published article will remain online except in extraordinary circumstances (e.g. where deemed legally necessary, or if the availability of the published content poses public health risks).

Expressions of Concern

Expressions of Concern may be issued at the discretion of the Editor if:

• there is inconclusive evidence of research or publication misconduct by the authors;
• there is evidence that the findings are unreliable but the authors’ institution will not investigate the case;
• an investigation into alleged misconduct related to the publication either has not been, or would not be, fair and impartial or conclusive;
• an investigation is underway but a judgment will not be available for a considerable time.

Upon completion of any related investigation, and when a final determination is made about the outcome of the article, the Expression of Concern may be replaced with a Retraction notice or Correction.

At ACS Publications, we know it is important for you to be able to share your peer reviewed, published work with colleagues in the global community of scientists. As sharing on sites known as scholarly collaboration networks (SCNs) is becoming increasingly prevalent in today’s scholarly research ecosystem, we would like to remind you of the many ways in which you, a valued ACS author, can share your published work .

Publishing open access makes it easy to share your work with friends, colleagues, and family members. In addition, ACS Publications makes it easy to share your newly published research with ACS Articles on Request (see below). Don’t forget to promote your research and related data on social media, at conferences, and through scholarly communication networks. Increase the impact of your research using the following resources: Altmetrics , Figshare , ACS Certified Deposit

When your article is published in an ACS journal or partner journal, corresponding authors are provided with a link that offers up to 50 free digital prints of the final published work. This link is valid for the first 12 months following online publication, and can be shared via email or an author’s website. After one year, the access restrictions to your article will be lifted, and you can share the Articles on Request URL on social media and other channels. To access all your Articles on Request links, log in to your ACS Publishing Center account and visit the “My Published Manuscripts” page.

Article , journal , and commercial reprints are available to order.

Appendix 1: PREPARING FOR SUBMISSION

We’ve developed ACS’ publishing and editorial policies in consultation with the research communities that we serve, including authors and librarians. Browse our policies below to learn more.

Ethical Guidelines

ACS editors have provided Ethical Guidelines for persons engaged in the publication of chemical research—specifically, for editors, authors, and reviewers. Each journal also has a specific policy on prior publication .

OFAC Compliance

As a U.S.-based non-profit organization, the American Chemical Society (ACS) is required to comply with U.S. sanctions laws and regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Control (OFAC). While these laws and regulations permit U.S.-based publishers like ACS to engage in publishing-related activities with authors located in sanctioned regions in many cases, ACS may be prohibited under U.S. law from engaging in publishing-related activities in some cases, including, but not limited to, instances where an author or the institution with which an author is affiliated is located in a particular sanctioned region or has been designated by OFAC as a Specially Designated National (SDN) pursuant to certain U.S. sanctions programs. ACS reserves the right to refrain from engaging in any publishing-related activities that ACS determines in its sole discretion may be in violation of U.S. law.

Safety Considerations

Authors must emphasize any unexpected, new, and/or significant hazards or risks associated with the reported work. This information should be in the Experimental Section of a full article and included in the main text of a letter. Statement examples can be found in the Safety Statement Style Sheet  and additional information on communicating safety information from the  ACS Guide to Scholarly Communication is freely available here .

Conflict of Interest Disclosure

A statement describing any financial conflicts of interest or lack thereof is published in each ACS journal and partner journal article.

During the submission process, the Corresponding Author must provide a statement on behalf of all authors of the manuscript, describing all potential sources of bias, including affiliations, funding sources, and financial or management relationships, that may constitute conflicts of interest. If the manuscript is accepted, the statement will be published in the final article.

If the manuscript is accepted and no conflict of interest has been declared, the following statement will be published in the final article: “The authors declare no competing financial interest.”

In publishing only original research, ACS is committed to deterring plagiarism, including self-plagiarism. ACS Publications uses CrossCheck's iThenticate software to screen submitted manuscripts for similarity to published material. Note that your manuscript may be screened during the submission process.

Further information about plagiarism can be found in Part B of the Ethical Guidelines to Publication of Chemical Research . See also the press release regarding ACS' participation in the CrossCheck initiative.

Authorship, Author List, and Coauthor Notification

Authors are required to obtain the consent of all their coauthors prior to submitting a manuscript. The submitting author accepts the responsibility of notifying all coauthors that the manuscript is being submitted.

During manuscript submission, the submitting author must provide contact information (full name, email address, institutional affiliation, and mailing address) for all of the coauthors. Because all of the author names are automatically imported into the electronic Journal Publishing Agreement , the names must be entered into ACS Paragon Plus. (Note that coauthors are not required to register in ACS Paragon Plus.) Author affiliation should reflect where the work was completed, even if the author has since left that institution. Authors may include a note with a current address if their institution has changed since the work was completed.

To expedite the processing of your manuscript, please format your author and affiliation information according the guidelines in this link: https://pubsapp.acs.org/paragonplus/submission/author-address-information.pdf .

Criteria for authorship can be found in Part B of the Ethical Guidelines to Publication of Chemical Research . Artificial intelligence (AI) tools do not qualify for authorship. The use of AI tools for text or image generation should be disclosed in the manuscript within the Acknowledgment section with a description of when and how the tools were used. For more substantial use cases or descriptions of AI tool use, authors should provide full details within the Methods or other appropriate section of the manuscript.

If any change in authorship is necessary after a manuscript has been submitted, confirmation is required that all of the authors (including those being added or removed) have been notified and have agreed to the change. To provide this confirmation, authors are asked to complete and sign an authorship change form and provide the completed form to the appropriate editorial office.

Patent Activities and Intellectual Property

Authors are responsible for ensuring that all patent activities and intellectual property issues are satisfactorily resolved prior to first publication (ASAP or in issue). Acceptance and publication will not be delayed for pending or unresolved issues of this nature.

Open Researcher and Contributor ID (ORCID)

Authors submitting manuscript revisions are required to provide their own personal, validated ORCID iD before completing the submission, if an ORCID iD is not already associated with their ACS Paragon Plus user profiles. This ID may be provided during original manuscript submission or when submitting the manuscript revision. All authors are strongly encouraged to register for an ORCID iD, a unique researcher identifier. The ORCID iD will be displayed in the published article for any author on a manuscript who has a validated ORCID iD associated with ACS when the manuscript is accepted.

ORCID iDs should not be typed into the manuscript. ACS publishes only those ORCID iDs that have been properly verified and linked before the manuscript is accepted . After your ORCID iD is linked, it will be displayed automatically in all subsequently accepted manuscripts for any/all ACS journals. We do not publish ORCID iDs provided during proof review or via other communications after a manuscript is accepted for publication.

With an ORCID iD, you can create a profile of your research activities to distinguish yourself from other researchers with similar names, and make it easier for your colleagues to find your publications. If you do not yet have an ORCID iD, or you wish to associate your existing ORCID iD with your ACS Paragon Plus account, you may do so by clicking on “Edit Your Profile” from your ACS Paragon Plus account homepage and following the ORCID-related links. Learn more at www.orcid.org .

Copyright and Permissions

To obtain forms and guidelines for copyright transfer, obtaining permissions from copyright owners, and to explore a Copyright Learning Module for chemists, click here .

Funder Reporting Requirement

Authors are required to report funding sources and grant/award numbers. Enter ALL sources of funding for ALL authors in BOTH the Funder Registry Tool in ACS Paragon Plus and in your manuscript to meet this requirement.

Open Access Compliance

ACS offers options by which authors can fulfill the requirements for open access and deposition into repositories for funded research. Visit our ACS Open Science site to see how to fulfill requirements for specific funders  and to find out if you are eligible to publish under a Read + Publish agreement between ACS and your institution. You can also find out more about Open Access Compliance and ACS Open Science initiatives .

Appendix 2: Preparing Graphics

Digital graphics pasted into manuscripts should have the following minimum resolutions:

• Black and white line art, 1200 dpi
• Grayscale art, 600 dpi
• Color art, 300 dpi

Graphics must fit a one- or two-column format. Single-column graphics can be sized up to 240 points wide (3.33 in.) and double-column graphics must be sized between 300 and 504 points (4.167 in. and 7 in.). The maximum depth for all graphics is 660 points (9.167 in.) including the caption (allow 12 pts. For each line of caption text). Lettering should be no smaller than 4.5 points in the final published format. The text should be legible when the graphic is viewed full-size. Helvetica or Arial fonts work well for lettering. Lines should be no thinner than 0.5 point.

Color may be used to enhance the clarity of complex structures, figures, spectra, and schemes, etc., and color reproduction of graphics is provided at no additional cost to the author. Graphics intended to appear in black and white or grayscale should not be submitted in color.

Type of Graphics

Table of contents (toc)/abstract graphic.

Consult the Guidelines for Table of Contents/Abstract Graphics for specifications.

Our team of subject-matter experts and graphical designers can also help generate a compelling TOC graphic to convey your key findings. Learn more about our Graphical Abstract service .

A caption giving the figure number and a brief description must be included below each figure. The caption should be understandable without reference to the text. It is preferable to place any key to symbols used in the artwork itself, not in the caption. Ensure that any symbols and abbreviations used in the text agree with those in the artwork.

Charts (groups of structures that do not show reactions) may have a brief caption describing their contents.

Each table must have a brief (one phrase or sentence) title that describes the contents. The title should be understandable without reference to the text. Details should be put in footnotes, not in the title. Tables should be used when the data cannot be presented clearly in the narrative, when many numbers must be presented, or when more meaningful inter-relationships can be conveyed by the tabular format. Tables should supplement, not duplicate, information presented in the text and figures. Tables should be simple and concise.

Each scheme (sequences of reactions) may have a brief caption describing its contents.

Chemical Structures

Chemical structures should be produced with the use of a drawing program such as ChemDraw.

Journal of Medicinal Chemistry authors are encouraged to submit images to be considered for use on the journal’s front cover or Supplementary Covers at the time of the submission of their revised manuscript. If your article is accepted for publication, your suggestion may also be selected for use on one of the journal’s covers. If your art is selected for front cover, ACS will send you information about how to request one complimentary 18” by 24” printed poster featuring your work. Images chosen for the front cover will be published at no cost to the author.

Front covers should be both visually captivating and scientifically interesting to the medicinal chemistry field. Images should be colorful, without text or structures. Submissions of structures, graphs, and chemical schema are discouraged and will not be considered. Artistic renditions of molecules, cells and data are encouraged. Authors are strongly advised to visit the journal’s recent issues to review what has previously been accepted.

Image files should be submitted as TIF, JPG, PNG or EPS files with a resolution of at least 300 dpi for pixel-based images. Images should be 6.86 in × 5.31 in. (or 17.42 cm × 13.49 cm). Authors should submit the cover image, along with a short, clear legend (less than 50 words) explaining the image, as supplementary files to ACS Paragon Plus with their revised manuscript.

If you wish to be considered only for the front cover, and not a paid supplementary cover, please respond NO accordingly to the Journal Covers question in ACS Paragon Plus. For more information on the Supplementary Covers program, please see this webpage . All art submitted for consideration for a supplementary cover will also be considered for a front cover.

Web Enhanced Objects (WEO)

The Web editions of ACS journals allow readers to view multimedia attachments such as animations and movies that complement understanding of the research being reported.

WEOs should be uploaded in ACS Paragon Plus with ‘Web Enhanced Object’ selected as the file designation. Consult the list of compatible WEO formats .

1155 Sixteenth Street N.W. Washington, DC 20036

京ICP备13047075

Copyright © 2017 American Chemical Society

• Journals A–Z
• C&EN Archives
• ACS Legacy Archives

User Resources

• ACS Members
• Authors & Reviewers
• Website Demos
• Privacy Policy
• Mobile Site
• For Advertisers
• Institutional Sales
• Connect with ACS Publications

• Current USC Employees
• Returning Candidates

Search all jobs

Areas Of Work Select Administrative Operations Auxiliary Services Faculty Human Resources Information Technology Keck Medicine of USC

Employment Type Select Faculty Full Time Faculty Part Time Staff Full Time Staff Part Time

Let’s change the world together!

USC is a leading private research university located in Los Angeles – a global center for arts, technology and international business. As one of the city’s largest private employers, responsible for more than $8 billion annually in economic activity in the region, we offer the opportunity to work in a dynamic and diverse environment, in careers that span a broad spectrum of talents and skills across a variety of academic schools and units. As a USC employee, you will enjoy excellent benefits and perks , and you will be a member of the Trojan Family - the faculty, staff, students and alumni who make USC a great place to work. Think you’ve got what it takes to join us? We invite you to search our open positions and apply!

Research Lab Technician - Medicinal Chemistry Core

USC Alfred E Mann School of Pharmacy and Pharmaceutical Sciences has established a state-of-the-art Medicinal Chemistry Core Laboratory (MCC) to support research efforts within the School, throughout the USC research environment, other research teams, and corporate partners in Southern California, as well as for external collaborators. MCC is equipped with a full-fledged synthetic chemistry laboratory at the Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences .

MCC is seeking a self-motivated, customer service-oriented individual who has hands-on experience in organic synthesis, instrumentation, and lab management. The successful candidate will work under the supervision of the Associate Director and will have an opportunity to work in a team-oriented environment that provides cutting-edge research services to advance research endeavors in the USC research community and for external collaborative partners. 

Job Responsibilities

MCC-Lab services (70%)

• Synthesizes, purifies and characterizes small molecules for the multiple ongoing projects in the lab.
• Develops Structure-Activity Relationships
• Observes appropriate safety requirements.
• Participates in planning, designing, and conducting highly technical and complex research projects under the direction of the supervisor.
• Writes clear, detailed experimental procedures in MCC-lab notebook for the purpose of reproducibility of scientific results and maintain all the required analytical data pertaining to the experiment such as NMR (1H, 13C, 19F, 31P-NMRs), LC-MS/MS, HRMS and HPLC.
• Operates and maintains scientific equipment.

Administrative assistant (30%)

• Develop and assist to organize files, records, and SOPs.
• Manage stock and order inventories.
• Prepare reports and other MCC-administrative work as directed by the supervisor.
• Promote MCC-Lab services; speak at campus events.

The ideal candidate will possess.

• Ability to quickly learn to operate and maintain a wide range of equipment and technology
• Ability to successfully prioritize and complete multiple ongoing projects in fast-paced environment
• Excellent interpersonal communication skills: advanced fluency in written and oral English.
• Strong customer service orientation with professional, ethical behavior and positive, team-oriented attitude.

Preferred Qualifications:

Minimum Education: Bachelor’s degree in related science field.

Minimum Experience: At least 1 year of hands-on experience in basic research.

Minimum Qualifications: Hands-on research experiences in designing and executing chemical synthesis.

Preferred Qualifications: Experience in organic synthesis

The hourly rate range for this position is $22.00 - $23.56.  When extending an offer of employment, the University of Southern California considers factors such as (but not limited to) the scope and responsibilities of the position, the candidate’s work experience, education/training, key skills, internal peer equity, federal, state, and local laws, contractual stipulations, grant funding, as well as external market and organizational considerations.

Job matching

With just one click and a connection to LinkedIn, we can connect you with jobs that match your work experience.

Stay connected with University of Southern California

Sign up to receive job alerts

Job Category

Email Address

LinkedIn Profile

Confirm Email

Recently added jobs

• Surgical Technician II - Outpatient Surgery Center - Full Time 12 Hour Rotating Shifts (Non-Exempt) (Union) Los Angeles, California REQ20128568
• Surgical Tech II - Outpatient Surgery Center (HC3) - Full Time 12 Hour Rotating Shifts (Non-Exempt) (Union) Los Angeles, California REQ20117535
• Surgical Tech II - OPSC HC3 - Full Time 12 Hour Rotating Shifts (Non-Exempt) (Union) Los Angeles, California REQ20129879

Herbal Medicinal Products Market Recent Trends, In-depth Analysis, Market Size Research Report Forecast up to 2030

This research report will give you deep insights about the Herbal Medicinal Products Market and it will also help you in strategic decision making. The final research document is an exhaustive document comprising of 150 pages. All our reports are usually purchased across industries by Executives, Managers, Senior Managers, Strategy people, Directors, Vice Presidents, CXOs, etc. and help them in understanding about the market trends and analysis, competition, industry landscape, market size, market revenue, forecast, COVID-19 impact analysis, SWOT analysis, etc.

Get a Sample copy of Herbal Medicinal Products Market research [email protected]   https://www.theinsightpartners.com/sample/TIPRE00007342/

The medical herbal products are traditional herbal medicines which exclusively containing as active ingredients one or more herbal substances, one or more herbal preparations, or a combination of the two.

The List of Companies

•  N A Nelson and Co
•  Hahnemann Laboratories, inc.
•  Nature's Way Products, LLC
•  Arizona Natural Products
•  Traditional Medicinals
•  Blackmores
•  Himalaya Global Holdings Itd
•  Ganoherb International Inc
•  DSM (koninklijke dsm n.v)
•  Ricola

The research provides answers to the following key questions:

• What is the estimated growth rate of the market for the forecast period 2020–2030? What will be the market size during the estimated period?
• What are the key driving forces responsible for shaping the fate of the Herbal Medicinal Products market during the forecast period?
• Who are the major market vendors and what are the winning strategies that have helped them occupy a strong foothold in the Herbal Medicinal Products market?
• What are the prominent market trends influencing the development of the Herbal Medicinal Products market across different regions?
• What are the major threats and challenges likely to act as a barrier in the growth of the Herbal Medicinal Products market?
• What are the major opportunities the market leaders can rely on to gain success and profitability?

Key Benefits

• The study provides an in-depth analysis of the global Herbal Medicinal Products Market to elucidate the prominent investment pockets.
• Current trends and future estimations are outlined to determine the overall attractiveness and single out profitable trends to gain a stronger foothold in the market.
• The report provides information related to key drivers, restraints, and opportunities and their impact analysis.
• The market is analyzed based on various regions, namely, North America, Europe, Asia-Pacific, and LAMEA.

Every crucial and decisive detail for the development of the market and the restraining factors that may hamper the market in near future is mentioned with solutions in the report. Segmentation of the Herbal Medicinal Products Market are studied specifically to give profound knowledge for supplementary market investments.

Interested in purchasing this Report?  Click here @  https://www.theinsightpartners.com/buy/TIPRE00007342/

About The Insight Partners:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Ankit Mathur E-mail:  [email protected] Phone: +1-646-491-9876

Newsmantraa

• Veterinary Ivermectin Market Global Analysis of Key Manufacturers, Dynamics & Forecast 2020-2030
• Cloud Data Integration Market 2023-2030 Worldwide Major Industry & Top Players are | Autoliv, Delphi, Robert Bosch
• Ultra Wideband (UWB)Market Is Booming Across the Globe Explored in Latest Report 2023-2030 | Decawave Ltd., TDC Acquisition Holdings,Texas Instruments Incorporated
• Testing, Inspection and Certification Services Market analysis, Size, applications share, trends and Forecast 2022-2032 | TÜV Rheinland AG (Germany), Applus+ (Spain), and ALS (Australia)
• Sorting Cash Machine Market is anticipated to be highest growth and forecast 2021-2031 | Julong Europe GmbH, GRGBanking, Bcash Electronics Co., Laurel
• Electric Forklift Market to increase at a high CAGR of 15.6% by 2032 | Toyota, Kion, Jungheinrich, Mitsubishi Logisnext, Hyster-Yale, Crown Equipment
• Prenatal and Newborn Genetic Testing Market to surpass USD 20.9 Billion by 2032 | Ariosa Diagnostics (Roche), Berry Genomics, BGI, Biorad, Illumina
• Automated Cell Counters Market to grow at nearly CAGR of 5.9% By 2031 | Olympus Corporation, Agilent Technologies, Inc., and PerkinElmer, Inc
• HVAC Software Market SWOT analysis, growth, share, size and demand outlook by 2031 | Emerson, Honeywell, Mitsubishi Electric, Samsung, Nortek
• Multiplex Detection Immunoassay Industry: Mapping Innovations in Simultaneous Biomarker Analysis (2023-2033)
• Let’s waltz! Vienna ball season back in full swing
• ‘Avatar 2’ success proves cinema in post-pandemic ‘resurgence’: Cameron
• North of Soledar, Ukrainians yearn for peace
• Carlo Marks talks about his new Hallmark movie ‘The Wedding Veil Inspiration’
• Musk faces US fraud trial over Tesla tweet
• Heat home to be renamed Miami-Dade Arena
• States with the biggest gun industries
• 25 successful musicians who retired early
• French Muslim union sues nation’s biggest literary star Houellebecq
• Iconic child stars of the ’60s